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ABSTRACT
Introduction: Binge Eating Disorder (BED) is a common mental disorder, closely associated with 
obesity. Existing treatments are only moderately effective with high relapse rates, necessitating 
novel interventions. This paper describes the rationale for, and protocol of, a feasibility randomised 
controlled trial (RCT), evaluating the combination of transcranial Direct Current Stimulation (tDCS) 
and a computerised cognitive training, namely Approach Bias Modification training (ABM), in 
patients with Binge Eating Disorder who are overweight or obese. The aim of this trial is to obtain 
information that will guide decision making and protocol development in relation to a future large-
scale RCT of combined tDCS + ABM treatment in this group of patients, and also to assess the 
preliminary efficacy of this intervention. Methods and analysis:  66 participants with DSM-5 
diagnosis of BED and a body mass index (BMI) of >25 kg/m2 will be randomly allocated to one of 3 
groups: ABM + real tDCS; ABM + sham tDCS or a waitlist control group. Participants in both 
intervention groups will receive 6 sessions of ABM + real/sham tDCS over 3 weeks; engaging in the 
ABM task while simultaneously receiving bilateral tDCS to the dorsolateral prefrontal cortex. ABM is 
based on an implicit learning paradigm in which participants are trained to enact an avoidance 
behaviour in response to visual food cues. Assessments will be conducted at baseline, post-
treatment (3 weeks), and follow-up (7 weeks post-randomisation). Feasibility outcomes assess 
recruitment and retention rates, acceptability of random allocation, blinding success (allocation 
concealment), completion of treatment sessions and research assessments. Other outcomes include 
eating disorder psychopathology and related neurocognitive outcomes (i.e. delay of gratification and 
inhibitory control), BMI, other psychopathology (i.e. mood), approach bias towards food, and 
surrogate endpoints (i.e. food cue reactivity, trait food craving, and food intake).
Ethics and dissemination: This study has been approved by the North West - Liverpool East Research 
Ethics Committee. Results will be published in peer-reviewed journals.
Trial registration number: ISRCTN35717198
Strengths and limitations of this study
 The ICARUS study is the first randomised controlled feasibility trial of multi-session 
transcranial Direct Current Stimulation (tDCS) combined with Cognitive Bias Modification 
training (CBM) for adults with Binge Eating Disorder.
 ICARUS will compare [tDCS + CBM] vs. [sham tDCS + CBM] and a wait-list control group.
 ICARUS is designed to answer questions about the efficacy of the treatments tested.
 Results would need to be replicated in a larger trial before recommendations for tDCS + 
CBM as a treatment adjunct for patients receiving outpatient treatment for BED can be 
made.
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INTRODUCTION
Binge Eating Disorder (BED) is the most prevalent eating disorder (ED) worldwide, with 1-3% of the 
general population meeting diagnostic criteria[1,2]. Binge eating is a core symptom, characterised by 
consumption of large amounts of food, a sense of loss of control, and significant distress. Nearly 80% 
of those with lifetime BED have a comorbid psychiatric disorder, such as mood, anxiety, substance 
use disorders or another ED[2]. Due to the lack of compensatory behaviours (e.g. vomiting, excessive 
exercising), BED is often accompanied by, or leads to, obesity and associated physical 
complications[3,4]. In the general population, approximately 30-42% of people with BED are 
obese[2,5,6]. Around 30% of treatment-seeking obese people[7–9] and up to 47% of bariatric 
surgery candidates have full or partial BED[1,10,11]. Whilst BED itself has considerable individual and 
societal costs[12], the combination of BED and obesity is associated with more severe obesity, 
greater medical and psychiatric comorbidity, greater functional impairment and perinatal 
complications[12–15]. Treatments for BED and obesity are sub-optimally effective, with cognitive 
behavioural therapy (CBT) and some medications reducing binge eating and related 
psychopathology[1], and approximately 50-60% of patients achieving abstinence from bingeing at 
the end of treatment[18] with some sustained cessation at follow-up[19]. However, drop-out rates 
in established BED treatments reach 12-34%, and 30%-50% of BED patients relapse in long-term 
follow-ups[20–22], indicating that a substantial proportion do not maintain binge eating remission. 
Lisdexamfetamine[23] and topiramate[24] also reduce weight in the short-term but have 
considerable side effects[25], and their longer term efficacy is uncertain. Thus, there is a need for 
novel treatment developments.  
The aetiology of BED is widely seen as multi-factorial. Emerging neurobiological models emphasise 
both the role of stress in the onset and maintenance of the disorder[26,27], and the development of 
addiction-like features; craving, tolerance and binge escalation over time[28,29], impulsivity and 
compulsivity, alterations in executive function and attention[30] and reward-related decision 
making[31]. 
Upon encountering images of high-calorie food, BED patients report enhanced reward sensitivity 
and exhibit stronger medial orbitofrontal cortex responses compared to healthy controls and 
participants with bulimia nervosa[32]. In individuals with obesity, who may or may not have BED, 
activation in the ventral striatum (part of the reward system) has been found to be higher compared 
to normal-weight controls [33], in tandem with a more pronounced approach bias towards 
appetising food images [34,35], leading to greater likelihood of consumption. Furthermore, poor 
reward-related decision making behaviour may be a maintaining factor in obesity[36]. Converging 
data using different methodologies, such as brain imaging, eye tracking, and behavioural test 
paradigms [37] have found that patients with BED demonstrate a higher arousal rate in response to 
food stimuli, a concurrent motor plan to start eating, a higher reward sensitivity, and greater 
inhibitory deficits as compared to individuals without BED[32,38,39]. Those with obesity and BED 
(compared to obesity alone) have demonstrated that their attentional bias to food images held 
higher motivational value[40], and responded more to high calorie food images in sites of cognitive 
planning of motor movements, driven by emotions, which may reflect impulsive tendencies in the 
face of a binge-eating trigger. This tendency to approach and consume palatable food items may 
thus be compounded by a greater sensitivity to reward and a decreased capacity to inhibit action 
tendencies. This is corroborated by the recent finding that individuals with BED or Bulimia Nervosa 
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(BN) show higher food cue reactivity (increased cravings) when exposed to visual food cues 
compared to healthy controls [41]. Such accumulating evidence of BED as a unique diagnostic group 
situates it as a distinct phenotype within the obesity spectrum that is characterised by increased 
impulsivity [42].
Conventional treatments of BED, such as CBT may not be best suited to target highly automatic 
cognitive processes that occur at an early stage in information processing and that are considered to 
contribute to food craving and associated maladaptive cognitions/behaviours. Two “brain-directed” 
treatments may provide an avenue for modifying these processes: Approach Bias Modification 
training (ABM) and transcranial Direct Current Stimulation (tDCS).
Approach Bias Modification training (ABM) is a form of cognitive bias modification training (CBM) 
that aims to retrain approach bias tendencies (reach out towards) into avoidance ones (move away 
from)[43] regarding stimuli such as appetitive cues. Participants are systematically trained to show 
an avoidance movement in response to illness-related rewarding stimuli (e.g. food or alcohol) on a 
computer screen. ABM techniques have shown potential in several pilot and large-scale randomised 
controlled studies to treat alcohol[44] and tobacco[45] addictions, and to reduce consumption of 
cannabis[46] and unhealthy foods[47,48]. ABM has also yielded promising results in people with high 
levels of food craving and in bulimic eating disorders, including BED[49,50]. However, mixed results 
in empirical studies across these domains[51,52] raise methodological issues of ABM studies to date, 
such as low statistical power and suboptimal choice (or absence) of control groups[53] and 
administration of single versus multiple training sessions.
Transcranial Direct Current Stimulation (tDCS) is a form of non-invasive brain stimulation (NIBS) that 
has been used as a treatment adjunct for a range of psychiatric disorders, such as depression, 
schizophrenia and addictions[54–56]. Preliminary evidence suggests that tDCS and other forms of 
non-invasive brain stimulation are promising tools to reduce food craving, ED symptoms and body 
weight in bulimic EDs, including BED, and obesity[57]. Additionally, some studies indicate that NIBS 
may reduce depression/stress levels and improve reward-based decision making in ED patients[58]. 
A frequent stimulation target is the dorsolateral prefrontal cortex (dlPFC) which plays a major role in 
cognitive-inhibition, emotion regulation, and reward processing[58–61]. Although precise 
mechanisms of action of tDCS have yet to be understood, a key hypothesis in relation to BED is that 
enhancing dlPFC activity via tDCS alters the reward-cognition balance towards facilitation of 
cognitive control and suppression of reward-related mechanisms driving food 
craving/overeating[62]. 
If given concurrently (i.e. ‘online training’), NIBS is reported to boost the effects of cognitive training 
on the reduction of cognitive biases and the improvement of response inhibition[63]. NIBS may 
enhance synaptic strength in neuronal pathways activated by cognitive training, amplifying effects of 
training, and thus cognitive bias modification efficacy [64]. As the effectiveness of tDCS may thus be 
improved by pairing administration with a cognitive task inducing activity in the target brain 
region[65–67], such combined treatment interventions have been investigated among alcohol 
dependent inpatients (ABM and tDCS)[68], and to enhance inhibitory control related to food 
consumption (Go/No-Go Task and tDCS)[65]. The insignificant findings from these studies warrant 
commentary that to date, studies that have found positive effects of tDCS have either included 
obese participants or have had multisession protocols[65,69–71]. As this study incorporates both 
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aspects, it is optimally designed to yield significant results.
 
In light of both the individual and societal burden incurred by the rising prevalence of BED and 
obesity, research interventions informing treatments that lead to stable and long-lasting remission 
are of critical importance, and novel therapies may play a role in serving as adjuncts to treatment as 
usual, to enhance improvement in clinical outcomes obtained from engaging with eating disorder 
treatment services.  This research trial is the first to combine two promising novel intervention 
strategies in an integrated treatment and will yield important findings to shape future clinical trials. 
The intervention conditions of this feasibility study will involve 6 sessions of concurrent ABM and 
real or sham tDCS over 3 weeks, and will assess participant acceptability and dropout rates at this 
treatment frequency and duration. Additionally, the frequency of participants’ ED symptoms and 
other outcomes related to general psychopathology and neurocognition will be measured before 
and after the study interventions to assess treatment success. In summary, this proof-of-concept 
and feasibility study will establish the utility of concurrent ABM + real tDCS in improving clinical 
outcomes in participants with BED, compared to ABM + sham tDCS, and a wait-list control group. 
STUDY AIMS 
In line with established recommendations for outcomes of feasibility trials[72], which at present are 
supported by the National Institute for Health Research, the primary aim is to assess the feasibility of 
using concurrent ABM + real tDCS compared to concurrent ABM + sham tDCS as a potential adjunct 
to treatment as usual (TAU) in this patient population, and acquire key information to inform the 
development of a large-scale randomised sham-controlled trial (RCT). 
The specific objectives of the proposed feasibility study are to:
1. Establish the feasibility of conducting a large-scale RCT of ABM + tDCS in patients with BED 
by assessing recruitment, attendance, and retention rates;
2. Determine the practicality of administering both ABM and tDCS simultaneously;
3. Determine the best instruments for measuring outcomes in a full trial by examining the 
quality, completeness, and variability in the data;
4. Estimate the treatment effect sizes and standard deviations for outcome measures to inform 
the sample size calculation for a large-scale RCT;
5. Evaluate whether the treatment is operating as it is designed by analysing process measures, 
such as within-session visual analogue scales (VAS) of key ED symptoms;
6. Determine whether patients with BED evaluate concurrent ABM + tDCS as acceptable and 
credible;
7. Obtain information about patients’ willingness to undergo random allocation to ABM paired 
with either real or sham tDCS administration, or the wait-list control condition.
A secondary aim is to investigate the potential efficacy of concurrent delivery of both forms of 
treatment on binge eating disorder.
This will involve evaluating if:
1. Concurrent sessions of ABM + real tDCS are superior to ABM + sham tDCS and to wait-list 
control in terms of frequency of objective binge eating episodes, food cue reactivity, food 
craving, food intake, eating disorder psychopathology and mood.
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2. Concurrent ABM + tDCS is superior to the two other conditions in having an effect on the 
targeted neurocognitive mechanism (approach bias for high calorie food) and related 
neurocognitive parameters (i.e. impulsivity, delayed gratification, emotional regulation).
3. Concurrent ABM and sham tDCS is superior to the waitlist control in eliciting therapeutic 
effects on the aforementioned clinical outcomes and neurocognitive mechanisms, yet 
demonstrates an efficacy level below that of concurrent ABM and real tDCS.
METHODS AND ANALYSIS
This study protocol has been written according to the SPIRIT statement (Standard Protocol Items for 
Randomised Trials)[73] and the CONSORT 2010 statement (Consolidated Standards of Reporting 
Trials)[72].
Study design 
The ICARUS trial (Investigating Concurrent Approach Bias Modification Training and Transcranial 
Direct Current Stimulation in Binge Eating Disorder) is an exploratory randomised controlled 
feasibility trial with three parallel treatment conditions; ABM + real tDCS, ABM + sham tDCS and 
wait-list control. All participants across the two intervention groups will receive a treatment protocol 
of 6 sessions of ABM + real/sham tDCS conducted over 3 weeks. The comparator groups of a wait-list 
control and ABM + sham tDCS are necessary to evaluate the potential effect of real versus sham 
tDCS in participants with BED.  The wait-list control group will be examined at the same time points 
to control for the possibility that improvements in the intervention groups are simply due to 
regression to the mean, spontaneous remission or other non-specific time effects. Any participants 
who are engaging in treatment for their ED will continue with TAU, and thus this selection of 
comparators is deemed acceptable. Within treatment session measures will involve visual analogues 
scales evaluating mood, stress and eating disorder symptoms. Assessments will be conducted 3 
times during the study; at baseline, post-treatment (week 3), and at follow-up (week 7). 
Participants
Inclusion criteria entail: (1) male and female community-dwelling adults (aged 18-70); (2) overweight 
or obese according to WHO criteria (BMI>25 kg/m2)[74]; (3) a diagnosis of full-syndrome or sub-
threshold Binge Eating Disorder according to the DSM-5[75]L; (4) fluency in English; (5) normal or 
corrected to normal vision .
Exclusion criteria entail: (1) all known contraindications to tDCS[76]; (2) pregnancy; (3) a current 
significant/unstable medical or psychiatric disorder needing acute treatment in its own right; (4) a 
lifetime diagnosis of substance dependence, psychosis, bipolar disorder or borderline personality 
disorder; (5) taking psychotropic medication other than a stable dosage of selective serotonin 
reuptake inhibitors (SSRI) for at least 14 days prior to study enrolment; (6) allergies to any of the 
foods presented in the study; (7) smoking >10 cigarettes per day; (8) drinking >3-4 units (men) or 2-3 
units (women) of alcohol per day. In line with the CONSORT guidelines[77,78], we will record the 
number and reasons for any participants we must exclude, or any who decline consent or withdraw 
from the study.
Sample size
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As ICARUS is a feasibility study, an a priori sample size calculation is not necessary. Rather, its aim is 
to provide effect sizes on which future large-scale studies can be powered. Total study sample sizes 
of n=24 to n=50 have been recommended for feasibility trials with a primary outcome measured on 
a continuous scale, mainly because estimates of the standard deviation for normally distributed 
variables tend to stabilise around this size[79,80]. We have chosen a target end study sample size of 
n=60, (i.e. exceeds the upper end recommended for feasibility trials). However, assuming the 
attrition to follow-up rate is a = 0.10 (as found in previous eating disorder trials [81,82]) and applying 
an attrition correction factor of 1/(1-a), we will recruit an actual sample size of 66, i.e., 22 
participants per group.
Randomisation 
After the baseline assessment, participants will be allocated to one of three conditions at random to 
receive 6 sessions of either concurrent ABM + real tDCS or ABM + sham tDCS, or no intervention in 
the wait-list control condition. As a proportion of participants recruited from an outpatient eating 
disorder clinic will be on a waiting list to receive treatment at the time of enrolment in this study and 
may commence treatment shortly after study enrolment, this study will not seek to balance groups 
in terms of therapy engagement or medication usage. Participants in the wait-list control group will 
be offered the opportunity to receive ABM + real tDCS after the end of the follow-up. Participants 
will be individually randomised on a 1:1:1 ratio to the intervention or control groups in equal 
numbers. The generation and implementation of the randomisation sequence will be conducted 
independently from the trial team through a randomisation administrator who is not involved in any 
recruitment or research activity related to the ICARUS study. Online randomisation software (Sealed 
Envelope, London, UK) will be used for this purpose. Upon participant enrolment, the researcher will 
contact the randomisation administrator, who will inform this researcher in charge of carrying out 
the intervention of the participant's allocation via phone or email. 
Blinding
Double blinding is implemented only for the intervention group cohorts of the trial. The research 
assessor will remain blind to each participant’s tDCS assignment within the two intervention 
conditions until after the participant has completed the follow-up assessment. This double blinding 
protocol will be ensured via administration of the tDCS (NeuroConn DC-STIMULATOR PLUS) using 
“study mode”. This involves a five-digit numerical code unique to each patient will be inputted into 
the device prior to the participant’s testing session, that will initialise either sham or real (active) 
stimulation. The tDCS administrator and participants will remain blind to tDCS stimulation type 
throughout the study. Set-up of the randomisation codes and programming of the tDCS device will 
be performed by an investigator not involved in the trial. To assess blinding success, each participant 
and the researcher will be asked to guess the treatment allocation at the end of the 6 treatment 
sessions and to indicate how certain they are of this guess. The study group allocation will be 
revealed to the participant after their follow-up assessment. In the event of a reported change in a 
participant’s medication, or a new clinical diagnosis made during their study participation, the early 
unblinding of study condition for an intervention group participant will be permissible. The trial 
database will be maintained ‘blind’ until the point of study data analyses.
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Recruitment
The study will take place at the Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s 
College London (KCL), UK. Participants will be recruited from the Eating Disorders Service at the 
South London and Maudsley NHS Foundation Trust, from the KCL research recruitment webpage and 
social media account, and via posters placed on notice boards on KCL campuses. Participants who 
have previously taken part in research at the KCL Eating Disorders Unit and who have consented to 
be informed of future studies may also be contacted. The ICARUS study will also be advertised on 
the Beat (National Eating Disorders Association) website, callforparticipants.com and 
www.mqmentalhealth.org. Potential participants will receive written and verbal study information 
and will be screened for eligibility. Eligible participants will provide informed written consent for 
study participation as a prerequisite for enrolment (See Appendices A and B). 
Procedure 
Figure 1 illustrates the timeline of the study procedures. All participants will partake in assessments 
at each of the three measurement points; baseline, post-treatment, and follow-up. Each assessment 
will comprise of an in-person study visit with tasks and measures, and online/hardcopy 
questionnaires and scales to be completed at home by the participant within 36 hours following the 
study visit. Table 1 details the tasks and measures allocated to each assessment and training visit. 
After the baseline assessment, participants are randomised to one of 3 groups; (1) ABM + real tDCS, 
(2) ABM + sham tDCS, or a waitlist control group (CG). Participants allocated to an intervention 
group will be offered 6 sessions of ABM + real/sham tDCS across 3 weeks. All study participants may  
receive TAU e.g. if they are currently engaged in outpatient treatment for their ED. The control 
group will not receive any study intervention, and any participants receiving outpatient services 
treatment for their ED will continue TAU during this 3 week period. The post-treatment assessment 
will be conducted on all participants after the 6th (final) session of ABM + real/sham tDCS for the 
intervention groups, and 3 weeks after the baseline assessment for the control group. The follow-up 
assessment will be conducted 28 days after the end of treatment, i.e. 7 weeks post-randomisation. A 
follow-up period is included because, if the effects of the intervention result from increased 
neuroplasticity, behavioural changes may need time to emerge. Assessing the longevity of 
favourable clinical outcomes beyond the treatment period is also relevant to the objectives of this 
feasibility study. The researcher conducting the assessment and testing sessions will remain blind to 
the study condition of intervention group participants until the follow-up has been completed.
Outcome assessment
Measures of feasibility, safety and adherence will be collected throughout the study. Outcomes 
related to ED symptoms, general psychopathology and neurocognition will be measured before and 
after the study intervention to assess treatment success. Each assessment session will be split into 
an in-person visit and at-home component to accommodate time constraints and minimise 
disruption to task performance due to participant fatigue. The in-person assessment measures will 
take approximately 75 minutes to complete, and the online questionnaires will take approximately 
45 minutes.
Outcome Measures  
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Feasibility outcomes
As this is a feasibility study, an extensive range of outcome measures are included to help determine 
which are most sensitive to detecting a treatment effect. This will enable us to determine primary 
outcome(s) for a future large-scale RCT. However, based on previous research[49], the Eating 
Disorder Examination Questionnaire (EDE-Q) is anticipated to be a key outcome measure.
Intervention/service related outcomes
Feasibility outcomes include recruitment, attendance and retention rates, and acceptability of 
treatment by participants. Patients’ acceptance of study interventions will be assessed by measuring 
treatment dropout rates and via the treatment tolerance and acceptability questionnaires. An 
interview assessment of treatment experience will be conducted with 20 participants after the 
follow-up is completed. 10 participants from each intervention group will be invited to provide 
feedback on their initial expectations and experiences of the ABM + real/sham tDCS treatments, 
perceived strengths and weaknesses of the treatment they received, and suggestions for 
improvements in procedures. Interviews will be recorded, transcribed and analysed using thematic 
analysis. This will allow future studies to consider patients’ feedback in the development of research 
and clinical protocols of concurrent ABM and tDCS.
Clinical outcomes
Eating disorder and related psychopathology
(a) Eating Disorder Examination (EDE-Q)[83]: The EDE-Q is a widely used measure of eating-
disordered behaviour and is widely regarded as the instrument of choice for the assessment of EDs. 
This will be administered at baseline, post-assessment and follow-up.
b) Body Mass Index (BMI (kg/m2)): This assessment of body composition provides accurate 
estimates of body fat percentages in adults, where sex and age are factored into the analysis 
measuring height and weight[84]. To calculate BMI, height and weight measurements will be 
obtained by the researcher at baseline, post-assessment and follow-up.
(c) Approach bias assessment tasks
To identify the most sensitive method of assessing change in approach bias towards high-calorie 
food items, two different computerised measures of approach bias will be used. In the Food 
Approach-Avoidance Task (F-AAT)[85] participants are shown colour photographs of high-calorie, 
palatable foods such as chocolate, cake, and pizza, and non-food household and office items such as 
sponges and stationary on a computer-screen[86]. They are instructed to approach and avoid these 
stimuli by moving a joystick toward themselves (approach) or away from themselves (avoidance). In 
the Stimulus Response Compatibility Task (SRC)[87], participants perform a symbolic movement by 
making a manikin image walk toward (approach) or away from stimuli (avoidance). See Appendix C 
for more detailed information. Both of these tasks will be administered at baseline, post-assessment 
and follow-up.
(d) Food choice attitudes/behaviour
The Food Choice Task[88–90] is a computer-based paradigm that measures responses to images of 
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foods to assess food attitudes and characteristics of eating behaviour. Participants rate images of 
food on a computer screen according to healthiness as well as tastiness. Based on these ratings they 
are then offered a choice between a food that they consider “neutral” and a series of other foods. 
See Appendix C for more detailed information. This task will be performed at baseline and post-
assessment.
(e) Food craving after cue exposure task
The Food Challenge Task (FCT)[41] will be used to examine cue-induced food craving. In this task, 
participants rate their state food craving using the Food Cravings Questionnaire State Version[91,92]  
before and after being presented with a video on a computer screen of foods shown to be highly 
appetising[93]. See Appendix C for more detailed information. This task will be performed at 
baseline and post-assessment.
(f) Trait food craving
Three questionnaires will be used to comprehensively assess mechanisms implicated in trait food 
craving. The Food Cravings Questionnaire Trait Version - reduced (FCQ-T-r)[94] is a 15 items only 
reduced version of a self-report questionnaire that measures trait levels of craving for food. The 21-
item Power of Food Scale (PFS)[95] scale assesses the psychological influence of the mere presence 
or availability of food. It measures appetite for, rather than consumption of, palatable foods, at 
three levels of food proximity (food available, food present, and food tasted). The Yale Food 
Addiction Scale Version 2.0 (YFAS 2.0)[96] reflects the current diagnostic understanding of addiction 
to further investigate the potential role of an addictive process in problematic eating 
behaviour[75,97–101]. See Appendix C for more detailed information. Each of these scales will be 
administered at baseline, post-assessment and follow-up.
(g) Food intake in a bogus taste test
During the bogus taste test[102], participants will be instructed to rate and optionally consume 
highly palatable high-calorie food items presented in 3 bowls. See Appendix C for more detailed 
information. This task will be performed at baseline and post-assessment.
(h) Increased preference for delayed rewards 
The Delay Discounting Task with Money and Food[103] examines whether small amounts of food 
would be discounted more steeply than money, as occurs with larger amounts. See Appendix C for 
more detailed information. This will be administered at baseline, post-assessment and follow-up.
(i) Inhibitory control 
The cued Go/No-Go computer task is a classic test of executive function, requiring effortful response 
inhibition, and measures impulse control by the ability to inhibit instigated, prepotent responses. A 
food specific go/no-go task[104] measures impulsivity and response inhibition with respect to food 
and nonfood items. The Stop Signal Task (SST)[105]measures inhibitory control. Participants are 
required to engage in a computer task but withhold their response in the presence of a stop signal. 
An adaptation of the food version of the SST[106] will facilitate a comparison of responses between 
food and non-food categories. See Appendix C for more detailed information. Both of these tasks 
will be performed at baseline, post-assessment and follow-up.
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Mood and emotion regulation
The Emotion Regulation Questionnaire (ERQ)[107] is designed to measure respondents’ tendency to 
regulate their emotions regarding cognitive reappraisal and expressive suppression. The Positive and 
Negative Affect Schedule (PANAS)[108] measures the degree of positive or negative affect 
experienced “right now” in the current study. The Depression, Anxiety and Stress Scale (DASS-
21)[109] evaluates mood, anxiety and stress levels over the previous week. See Appendix C for more 
detailed information. All of these measures will be administered at baseline, post-assessment and 
follow-up.
Within session measures 
Within each training session, i.e. immediately before and after the ABM + real/sham tDCS procedure 
the researcher will administer paper-based Visual Analogue Scales (VAS) assessing current hunger, 
feeling of fullness, urge to eat, urge to binge eat, feeling low, level of tension, level of stress, level of 
anxiety, and any discomfort due to tDCS and ABM in the training session. See Appendix C for more 
detailed information.
Intervention 
In both intervention groups participants will receive six sessions of concurrent ABM and real or sham 
tDCS which will be delivered twice a week for three weeks. A researcher trained in tDCS 
administration will deliver the training sessions. 
Rationale for number of sessions:
Treatment parameters for interventions of ABM and tDCS separately in psychiatric disorder research 
have not yet been standardised and vary from 1-12 sessions across a timeframe of days to multiple 
weeks. Mixed results regarding optimal frequency of ABM sessions and related forms of cognitive 
bias modification has been reported[110]. A maximum accumulative effect of modification efficacy 
at 6 sessions has been found for approach bias modification for alcohol dependence[44]. While 
there is a similar paucity of specifications for treatment parameters within tDCS, multisession NIBS 
interventions are significantly more effective at reducing cravings and strengthening the ability to 
refrain from food consumption than single session protocols in eating disorders and obesity[111]. As 
a single session of tDCS on patients with BED was found to reduce craving and caloric intake[59], it 
was hypothesised that repeated administration of tDCS would enhance this effect and may decrease 
binge eating frequency.
Within session safety procedures
The participant’s blood pressure and heartrate will be taken by the researcher immediately before 
and after the session. While the participant is comfortably seated, the tDCS and ABM will be 
administered at the same time, i.e. participants will engage in ABM training whilst receiving tDCS. 
Each session will last 20 minutes. The ABM training will start 5 minutes after the start of the brain 
stimulation. ABM training will take place over 10 minutes and tDCS will then continue for a further 5 
minutes. Participants will be reminded that they have the option to withdraw immediately and 
terminate their participation in the study if they experience discomfort during tDCS administration, 
or if they wish to withdraw for any reason that they may or may not wish to disclose. 
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Approach bias modification training
The ABM programme will use an implicit learning paradigm, based on a modified version of the Food 
Approach/Avoidance Task (AAT)[85,112–114]. In this task, participants are shown pictures of food 
and control (i.e. neutral office) items. They are required to pull (pictures grow bigger) or push 
(pictures grow smaller) a joystick in response to the outer frame of the picture (round vs. 
rectangular), irrespective of the picture content. The training version of the Food-AAT utilises an 
implicit learning paradigm by presenting all food pictures in the “push” (i.e. avoid) format. The study 
procedure for ABM administration is aligned with previous research[50,115].
Transcranial direct current stimulation
TDCS (both real and sham) will be delivered using a NeuroConn® DC-STIMULATOR PLUS device at a 
constant current of 2 mA (with a 10-second fade in/out) using two 25cm² surface sponge electrodes 
soaked in a sterile saline solution (0.9% sodium chloride). The anode will be placed over the right 
dorsolateral prefrontal cortex (dlPFC) and the cathode over the left dlPFC. This montage has been 
used in sham-controlled studies on food craving, bulimia nervosa and BED[59]. The stimulation site 
will be located using the Beam F3 calculation method, which is based on the International 10-20 
system. TDCS can occasionally result in mild discomfort during administration (i.e., tingling or itching 
sensation, a slightly metallic taste, occasional redness at the site of the electrodes). Fatigue, 
headache, nausea and insomnia have been reported as potential adverse reactions[116]. 
Participants who are at-risk for adverse effects[76] will be excluded from the study at the screening 
stage.
Data analysis
Data will be analysed with the Statistical Package of Social Sciences (SPSS). Feasibility outcome data 
will be analysed with appropriate summary statistics. To determine quality, completeness, and 
variability of the clinical outcome data, descriptive statistical analyses and graphical methods will be 
used. Intent-to-treat analyses will be performed. The size of the treatment effect on each outcome 
measure will be the difference in outcome data between those in the two treatment conditions and 
control condition at post-assessment and follow-up. Group differences will be estimated using linear 
mixed effects regression models, controlling for the baseline level of the outcome. The goal here is 
not to determine significant group differences but to establish a suitably precise effect size for the 
primary outcome at the post treatment assessment. This estimate will be used to guide the sample 
size of a future efficacy trial. Correlational analyses may be computed to analyse relationships 
between outcome variables and influences of potential covariates such as demographic variables, 
i.e. gender, age, BMI and clinical variables, i.e. start/stopping of psychotherapy, psychotropic 
medication and presence of comorbidities. Outcome data already obtained for participants who 
discontinue or deviate from the intervention protocol will be kept and analysed.
PATIENT AND PUBLIC INVOLVEMENT
Patients and/or public were not involved in the study design process, however we will obtain 20 
intervention participants’ qualitative views on their treatment experience in this study to inform 
future clinical trials.
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ETHICS AND DISSEMINATION
Data management and data monitoring
Participant data will be anonymised and all anonymised data will be stored electronically on a 
password protected computer at the IoPPN. All trial data will be stored in line with the General Data 
Protection Regulation (GDPR) 2018. Hard copies of participant-related data (i.e. GP letters) will be 
kept in locked cabinets at the IoPPN, King’s College London. The final trial data set will not be 
accessed by anyone other than members of the research team.
Data will be stored on manual files, university and laptop computers. There will be no personal data 
stored on laptop computers. Confidentiality and anonymity of all personal data will be retained 
throughout the entire study. Manual files will be securely locked in a lockable filing cabinet, and all 
electronic files will be password protected. Identifying information will be removed from the data, 
stored separately and replaced with a numeric identification code. All participants will be allocated a 
numeric code, which will be used to identify their data. The master list of names which correspond 
to each participant's numeric identification code will be stored electronically and will be password 
protected. This information will only be accessible to key researchers involved in the study.
The online component of the assessment will use Online Surveys software (formerly BOS). King’s 
College London uses this software for large scale surveys, and it is fully compliant with UK data 
protection laws. Participants will be emailed the link after the in-person component of each 
assessment session, and instructed to complete the second online component of the assessment 
within 36 hours. Participants will also have the option to receive and complete a hard copy version 
of the questionnaires with a stamped addressed envelope to post back to the study researcher at 
the IoPPN. 
It is intended that the results of this feasibility study will be reported and disseminated at national 
and international conferences. Research findings may also be disseminated through internal 
newsletters and publications in collaboration with Beat, the UK’s largest eating disorder charity.
Owing to the size and nature of this small-scale feasibility study, a data monitoring committee was 
not deemed to be required. There are no scheduled interim analyses and this trial may be 
prematurely discontinued by the Chief Investigator on the basis of new safety information.
Ethics and safety aspects
This study has been approved by the North West - Liverpool East Research Ethics Committee. This 
trial will be conducted in compliance with the study protocol, the Declaration of Helsinki, the 
principles of good clinical practice (ICH-E6 guideline), the ICH-E8 guideline and the principles of GCP 
and in accordance with all applicable regulatory requirements including but not limited to the UK 
policy framework for health and social care research. The ICARUS trial is registered with the 
International Standard Randomised Controlled Trial Number registry (number ISRCTN35717198). All 
participants will be asked by the study researcher to provide written informed consent prior to 
enrolment. Participants who are at-risk for adverse side effects[76]will be excluded from the study at 
the screening stage (i.e. such as those with pregnancy or epilepsy). Current safety parameters of 
tDCS administration regarding voltage amplitude and duration of brain stimulation sessions will be 
adhered to. Participants have the option to withdraw immediately and terminate their participation 
in the study if they experience discomfort during tDCS administration, or if they wish to terminate 
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their participation for any other reason that they may or may not wish to disclose. After each 
training session, participants will complete the tolerance, discomfort and side effects questionnaire 
to report any adverse effects of the intervention training session. The researcher will record this 
description of any reported adverse effects, and record the severity and duration of symptoms and 
how the adverse effect was managed at the following training session. If a participant reports a new 
clinical diagnosis or change in medication during their involvement in the study, a decision regarding 
their continued participation in the study will be made by the research team and withdrawal of the 
participant may be deemed necessary. Standard King’s College London insurance and NHS indemnity 
arrangements apply to this study. To promote study adherence, upon completion of the follow-up 
assessment, each participant will be reimbursed for their time, efforts and travel (£60 for 
assessments and up to £60 for travel expenses). Additionally, participants in the wait-list control 
group will be offered the opportunity to receive 6 sessions of ABM + tDCS after the follow-up. 
DISCUSSION
The ICARUS study represents the first feasibility study that aims to exploit a synergistic therapeutic 
effect by combining two brain-directed interventions in a single treatment intervention for BED. The 
rising clinical need of individuals with BED is currently met with few available psychological and 
neuropharmacological treatment options[117]. Therefore, such research advancing the 
identification and validation of novel therapies is greatly warranted.
This paper delineates the protocol for a feasibility trial which will inform future studies (i.e., provide 
effect sizes for a large RCT) and contribute to the extant research advocating brain-directed 
interventions for BED. The protocol aligns with current parameters of tDCS administration used to 
treat BED and BN[58,59] and utilises a multitudes of measures to identify the most appropriate and 
sensitive tools to detect treatment induced changes across pathological and neurocognitive 
domains. 
Pragmatic concerns related to the recruitment process entail ensuring a sufficient and consistent 
rate of participant enrollment to meet the target sample number within the allocated timeframe. 
Additionally, drop-out rates for CBT treatment among a BED cohort are moderately high (17–
30%)[118], thus study adherence will need to be monitored, with a revision of incentives/ 
reimbursement if necessary. Participants who were randomly allocated to the wait list control may 
avail themselves of 6 sessions of ABM + real tDCS after they have completed the study, which may 
promote recruitment and participant retention. Documenting the management of these issues will 
help to inform the development of a future large-scale RCT of this combined treatment adjunct for 
BED.
To conclude, investigating novel treatments for BED is an imperative issue. Combining ABM with 
tDCS is the strategic amalgamation of two techniques that have already demonstrated therapeutic 
efficacy in their own right. This feasibility RCT will be the first to systematically assess the 
acceptability and efficacy of a noninvasive, safe and potentially effective treatment adjunct to other 
therapies, which will enhance the ability of healthcare services to provide optimal care to patients 
with BED.
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Trial progress
Recruitment will commence in February 2018 and data collection is expected to be complete 
(including follow-up assessments) by April 2020. Any substantial protocol amendments will be 
communicated to investigators via email and to other parties as required. Amendments to the study 
protocol will be reported in publications reporting the study outcomes.
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Figure 1 Study procedure. The 3 assessment time points are baseline, post-assessment and follow-up. IG1 is 
intervention group 1; IG2 is intervention group 2, CG is the wait list control group.
Table 1 Study schedule of measurement and testing time points
________________________________
Approximate time since baseline
Screening of 
potential 
participants
-------
Baseline 
assessment 
(all 
participants)
 -------
Training: 6 
sessions of
ABM + real 
tDCS
0-3 weeks
Training: 6 
sessions of 
ABM + 
sham tDCS
0-3 weeks
Post- 
assessment 
(all 
participants
3 weeks
Follow-up 
(all 
participants)
7 weeks
Informed consent X
EDDS, SCID-I X
TDCS safety screening X
Demographic information X
EDE-Q[83] X X X
Inhibitory control tasks; Go/No-Go 
task[104], SST[106]
X X X
Delay Discounting Task with Money and 
Food[103]
X X X
Food related tasks; Food Choice Task[88], 
FCT, Bogus Taste Test[102]
X X
Approach bias assessment tasks; F-AAT[85], 
SRC[87]
X X X
Questionnaires & scales (incl. at home); 
EDRSQ[119], FCQ-T-r[94], PFS[95], YFAS 
2.0[96], ERQ[107], PANAS[108], BIS-11[120], 
CIA[121], DGI[122], DASS-21[109]
X X X
Pre-[tDCS + ABM] measures:
 -Multiple VAS, blood pressure, pulse
    X                        X
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Real or sham tDCS to dLPFC         X                        X
Approach Bias Modification training         X                        X
Post-[tDCS + ABM] measures: 
-Multiple VAS, blood pressure, pulse
        X                        X
Tolerance, discomfort and side effects          X                        X
Acceptability questionnaire X
Blinding assessment questionnaire X
BIS-11; Barrett Impulsiveness Scale, CIA; Clinical Impairment Assessment, DASS-21; Depression, Anxiety and Stress Scale, DGI; Delayed 
Gratification Inventory, EDDS; Eating Disorder Diagnostic Screen, EDE-Q; Eating Disorder Examination, EDRSQ; Eating Disorder Recovery 
Self Efficacy Questionnaire, ERQ; Emotion Regulation Questionnaire, FCQ-T-r; Food Cravings Questionnaire Trait Version – reduced, 
PANAS; Positive and Negative Affect Schedule, PFS; The 21-item Power of Food Scale, SCID-I; Structured Clinical Interview for Diagnostic 
and Statistical Manual (DSM) Axis I Disorders, SRC; Stimulus Response Compatibility Task, SST; Stop Signal Task, YFAS 2.0; The Yale Food 
Addiction Scale Version 2.0, .
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Baseline: Consent, 
questionnaires, 
scales and tasks 
Post-assessment: 
Questionnaires, 
scales and tasks 
Follow-up: 
Questionnaires, 
scales and tasks 
IG1: 6 sessions of ABM + real 
tDCS 
vs. 
IG2: 6 sessions of ABM + 
sham tDCS 
vs. 
CG: No intervention 
 
 
time 
3 weeks 4 weeks 
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Supplementary File
Appendix A: Information sheet for all participants
PARTICIPANT INFORMATION SHEET
ICARUS: An Investigation of Approach Bias Modification 
Training (ABM) and Transcranial Direct Current 
Stimulation (tDCS) in Binge Eating Disorder
IRAS Project ID: 244170
Research Ethics Committee reference number: 18/NW/0648We would like to invite you to participate in this postdoctoral research project which is being conducted by a PhD student for research and educational purposes.  You should only participate if you want to; choosing not to take part will not disadvantage you in any way. Before you decide whether you want to take part, it is important for you to understand why the research is being done and what your participation will involve.  Please take time to read the following information carefully and discuss it with others if you wish.  Part 1 tells you the purpose of this study and what will happen to you if you take part. Part 2 gives you more detailed information about the conduct of the study.  Please ask us if there is anything that is not clear or if you would like more information.  
PART ONE
What is the purpose of the study?Psychological therapy as a main treatment for Binge Eating Disorder (BED) may not be effective for many people and may not be readily accessible in some areas. Medical treatments for BED can have side effects and often do not remain effective in the long-term. Therefore, there is an ongoing need for the development of new treatments. 
Computerised approach bias modification training (ABM) is a specific form of cognitive bias modification (CBM) that has been used to successfully treat mental disorders such as anxiety, depression, and addictive disorders. This technique involves several sessions of computerised training, a procedure which has shown to be effective in reducing the severity of some eating disorder symptoms in people with BED and Bulimia Nervosa (BN). ABM works as such; automatic approach and avoidance tendencies towards food- related cues are modified by repeated training of arm movements in front of a computer screen. ABM has shown to reduce approach tendencies and attention towards food cues in a subclinical sample of eating disorders involving binge eating, but its efficacy on these features in people with full-syndrome eating disorders remains unclear. Further research is needed to examine if ABM is effective in reducing the frequency of binge eating episodes in people with BED.
Transcranial direct current stimulation (tDCS) is a non-invasive technique that is capable of stimulating specific brain areas. Research shows that the frontal areas of the brain play a role in the development and maintenance of eating disorders, including BED. Stimulating these brain areas to alter their functioning is therefore believed to have the 
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potential to reduce eating disorder symptoms. This involves the delivery of a low electrical current via small electrodes placed on the scalp. This procedure is widely used in research and is being applied in clinical settings. Recent research using tDCS on people with BED has suggested that it may be helpful in reducing immediate food intake and cravings, and may decrease the frequency of a desire to binge eat at home after the treatment.
Combining ABM and tDCSPrevious studies suggest that these two techniques potentially help people better regulate their behaviours through similar mechanisms in the brain. Delivering both treatments together at the same time may have a stronger effect on reducing eating disorder symptoms in people with BED than either of the treatments alone. This will be the first time that this specific combination of interventions is conducted on people with an eating disorder. In the present study, we aim to investigate combined ABM and tDCS as a treatment for BED by comparing the effect of 6 sessions of (ABM + real tDCS) vs. (ABM + placebo tDCS) across a 3-week period in adult men and women with BED. We will also compare these two groups against a control group. Participants will be allocated by chance to either one of two intervention groups, or to the control group. Participants in the intervention groups will receive 6 sessions of ABM delivered simultaneously with either real tDCS or a placebo version of tDCS. Participants assigned to the control group will not receive any intervention. We will measure eating disorder symptoms and other outcomes in all participants at baseline, post-treatment, and at the 4-week follow-up to assess outcomes of each study group. In particular, we are interested in changes in the frequency of binge eating and craving, and thought processes and emotions related to food and eating. We will also ask participants about their experience of this treatment. Participants assigned to the control condition will be offered 6 sessions of (ABM + real tDCS) after they have completed their involvement in the study. 
Why have I been invited?You are invited to participate if you are a male or female aged between 18 and 70 who has a current diagnosis of binge eating disorder (BED). We will be recruiting 66 participants in total. 
Do I have to take part?You do not have to take part in this experiment; it is your choice.  If you decide to take part, you will be asked to sign three identical consent forms. You will be free to withdraw from the study at any time without giving a reason. Whether you decide to take part or not will in no way influence your care or the timing of your treatment. 
What will happen to me if I take part and what will I have to do?If you decide you want to participate you will firstly be asked to engage in a telephone conversation with the researcher (lasting approximately 20 minutes) to confirm that you are eligible to take part. If you are, you will be invited to the Institute of Psychiatry, Psychology and Neuroscience (Kings College London, Denmark Hill Campus) for a baseline assessment session on a day that is convenient for both you and the researcher, in either the morning or the afternoon. On this day, the researcher will discuss the study with you in person, answer your questions, and if you are happy to take part, we will 
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ask you to sign three copies of a consent form: one for you to keep, one for us to keep, and one that will be sent to your general practitioner (GP). This baseline assessment visit is longer that the treatment visits and is comprised of an in-person visit and online questionnaires to complete at home. During the visit, you will give informed study consent, complete two questionnaires, neuropsychological tasks (brain puzzles), and a food task for which you will be asked to rate different foods.  This visit also involves an assessment version of the approach bias modification (ABM) training programme, which is a computer based-task involving pushing and pulling a joystick in response to shapes appearing on the computer screen. Weight and height will be measured at each assessment, and participants may choose not to see the figures recorded. Assessment visits will last 65-75 minutes. Within 36 hours after the in-person visit, you will be emailed a link to a series of questionnaires (assessing mood and eating disorder-related thoughts and habits) which will take 30-45 minutes to complete. There is also the option to complete these assessment questionnaires in hardcopy paper format.You will then be then randomised and informed of your randomly assigned study condition within a week. If you are assigned to one of the two intervention conditions, you will be asked to attend 6 sessions where you will perform the ABM task while receiving either real or placebo tDCS, in addition to completing the post-treatment and follow-up assessments. If you are assigned to the control group, you will not receive any intervention, and will be asked to attend the post-treatment and follow-up assessments. All 6 intervention sessions will be identical and last approximately 40–50 minutes. There is no need for any special preparation before the visits. Before and after each intervention session, you will complete some scales related to aspects of your mood and level of hunger. Your blood pressure and pulse will also be measured before and after each intervention session to monitor your wellbeing.During the (ABM + real/placebo tDCS) session you will sit on a comfortable chair facing a computer screen, with a joystick on a table in front of you. You will wear a plastic headband to keep the two tDCS electrodes in place (as shown in the diagram below). The electrodes will be placed in small sponges soaked in a salt water solution, so they might feel a bit wet against your head. The researcher will turn the machine on which will deliver the currents. Depending on your assigned study condition, you will receive real or placebo brain stimulation. The placebo session will be the same as the real session, but the tDCS machine won’t deliver any electrical current. Most people can’t tell the difference between real and placebo tDCS sessions.
Page 30 of 76
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
4
The tDCS will begin a few minutes prior to the start of the computer training programme, to allow participants to become used to the sensation before starting the ABM task on the computer. The training version of the ABM programme is a computer based-task involving pushing and pulling a joystick in response to shapes appearing on the computer screen. The tDCS will also continue for a few minutes after the ABM task has ended. You will then be asked to rate any discomfort experienced during the session due the tDCS.You will be asked to return to the Institute for 5 more identical intervention sessions within 3 weeks, leaving a gap of at least 24 hours between each session. The post-assessment will be conducted immediately after the 6th intervention session. This in-person visit comprising of the final intervention session plus the post-assessment will therefore last 90-120 minutes, with the online questionnaires to be completed within 36 hours after this visit (45 minutes). The follow-up assessment 4 weeks later will be similar to the baseline assessment. This final visit will therefore take 75 minutes, with the online questionnaires taking 45 minutes to complete at home afterwards.20 participants (10 participants from each intervention condition) will be invited to provide feedback on their experiences of study participation, initial expectations of the intervention, perceived strengths and weaknesses, and suggestions for improvements in an interview with the researcher. Declining this invitation to interview does not affect study payment.6 months after the baseline assessment, participants may be contacted by phone by a member of the King’s College London Eating Disorders Unit for a brief phone call to evaluate the presence of eating disorder symptoms. This 6 month check-in will allow any long-term therapeutic effects of the study treatment intervention to be evaluated. Participation in this phone call will not affect participant payment, which will have been administered earlier after the 1-month follow up assessment.
Expenses and paymentsUpon completion of the study, all participants will be paid a maximum of £60 for completing each of the three assessment sessions (comprised of an in-person visit and at-home questionnaires); the baseline assessment, post-treatment assessment and follow-up assessment (£20 each). This payment should be declared for tax and/or benefit purposes. If you are assigned to an intervention condition involving 6 sessions of brain stimulation and computer training, you may also be compensated up to £10 per day for your travel expenses on these intervention session days.   
What is expected from you as a participant? We would expect you to complete all assessment sessions (pre-, post-treatment, follow-up), and if you are randomised to an intervention group, to attend all 6 (ABM + real/placebo tDCS) sessions as scheduled. We ask you to inform us immediately if for any reason you suddenly find yourself unable to attend a scheduled session. 
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Please let us know of any health problem that has developed, or any new diagnosis made since you enrolled for the study. Further, we would ask you to let us know of any new medication or change in medication whilst you are taking part in the study. 
What are the possible disadvantages and risks of taking part? What are the side 
effects?Combined brain stimulation and cognitive training sessions are time-consuming and may cause fatigue from concentrating on the task.TDCS has been shown to be safe when used correctly in a clinical setting. However, you may find the procedure slightly uncomfortable. This is because a number of sensations can occur beneath the electrodes during stimulation including tingling, pain, itching, and burning. Not everyone feels these sensations or finds them uncomfortable, but if you do, remember you are free to stop the study at any point without giving an explanation. In some rarer cases, tDCS has been known to cause a headache, but this can be treated with mild painkillers (e.g. paracetamol). No side effects of ABM are known.We will assess any discomfort you may experience during intervention sessions throughout your involvement in the trial. 
What are the possible benefits of taking part?Unfortunately, there are no direct benefits to taking part in this study, but the information we get may help us to improve the treatment of BED in the future. 
What happens when the research study stops?When the research study stops, no further ABM + tDCS sessions will be available to those who have received 6 sessions. Participants in the control group will have the option of receiving 6 sessions of [ABM + real tDCS] once they have completed the waiting period and follow-up assessment.Participants assigned to one of the intervention groups can request to be informed if they had received ABM combined with real or placebo tDCS, once they have completed the follow-up assessment.
What if there is a problem?Any complaint about the way you have been dealt with during the study or any possible harm you might suffer will be addressed. Detailed information on this is given in Part 2.
Will my taking part in the study be kept confidential?Yes. We will follow ethical and legal practice and all information about you will be handled in confidence. The details are included in Part 2.
If the information in Part 1 has interested you and you are considering 
participation, please read the additional information in Part 2 before making a 
decision.PART TWO
What if relevant and new information becomes available?Sometimes we get new information about the treatment being studied. This is not expected to occur given the short time frame of participation (6 sessions across 3 
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weeks); however, if any new and relevant information becomes available during this time we will inform you immediately. You can then decide whether you wish to continue in the study. 
What will happen if I don’t want to carry on with the study?Your participation is voluntary and you do not have to take part in the study. You can change your mind at any point and terminate your participation without giving a reason to the researcher. You are free to withdraw from this study at any time without consequence. 
Will participation in this study affect my routine healthcare, or the waiting period 
for treatment for my eating disorder if I am currently on a waiting list?No. Participation in this study will have no impact on your treatment as usual, or waiting time if you are currently awaiting treatment for your eating disorder. We fully encourage you to begin treatment as provided by a health care professional as soon as it becomes available to you. We simply ask that you inform us of any changes to your treatment or medication while you are partaking in the study. 
What if there is a problem?If you have a concern about any aspect of the study, please ask the researcher (gemma.gordon@kcl.ac.uk, 0207 848 0183) who will do their best to answer your questions. 
What if I wish to make a complaint?If you remain unhappy and wish to formally complain, complaints to the IoPPN should be addressed to Dr Gill Dale. Director of Research Quality; Head, Joint R&D Office of South London and Maudsley NHS Foundation Trust and Institute of Psychiatry, Psychology & Neuroscience (IoPPN), P005, Institute of Psychiatry, Psychology & Neuroscience (IoPPN), King's College London, De Crespigny Park, London SE5 8AF. NHS complaints will follow NHS complaints procedures. 
Other sources of support for your eating disorderTo access support and treatment, please see your Eating Disorders clinician or your GP who will be able to advise you and refer you to the right service for you. You can also obtain further information and support from www.beateatingdisorders.org.uk, the national Eating Disorders charity. Should you wish to speak to someone outside of the university, please talk to your Eating Disorders clinician, GP, the Beat helpline, and/or one of the study researchers who is happy to liaise on your behalf if you so wish. The eating disorders charity Beat provides helplines for adults and young people which offer support and information to sufferers, carers and professionals. Further information can be found on their website www.beateatingdisorders.org.uk, or by ringing their helpline 0808 801 0677.
Will my taking part in the study be kept confidential?Your personal information and the data we collect from you will remain confidential at all times. It will also remain anonymous to everyone apart from the primary researchers. Manual files will be locked securely in a filing cabinet, which will be kept in a locked office in the KCL Section of Eating Disorders, Department of Psychological 
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Medicine, IoPPN, and all electronic files will be password protected. All information which is collected during the course of the research will be kept strictly confidential according to the General Data Protection Regulation (GDPR), brought into effect on 25th May, 2018. This new legislation creates some new rights for individuals to better reflect data protection challenges in the modern digital age, as well as strengthening some of the rights that currently exist under the Data Protection Act 1998.
How will my personal data be used and what are my rights?King’s College London is the sponsor for this study based in the United Kingdom. We will be using information from you in order to undertake this study and will act as the data controller for this study. This means that we are responsible for looking after your information and using it properly. King’s College London will keep identifiable information about you for four years after the study has finished.Your rights to access, change or move your information are limited, as we need to manage your information in specific ways in order for the research to be reliable and accurate. If you withdraw from the study, we will keep the information about you that we have already obtained. To safeguard your rights, we will use the minimum personally-identifiable information possible. You can find out more about how we use your information by contacting the Study Coordinator Gemma Gordon.KCL will use your name and contact details to contact you about the research study, and make sure that relevant information about the study is recorded for your care, and to oversee the quality of the study. Individuals from KCL and regulatory organisations may look at your medical and research records to check the accuracy of the research study. SLaM will pass these details to KCL along with the information collected from you.  The only people in KCL who will have access to information that identifies you will be people who need to contact you regarding your participation or audit the data collection process. The people who analyse the information will not be able to identify you and will not be able to find out your name or contact details. KCL will keep identifiable information about you from this study for four years after the study has finished.
Involvement of the General Practitioner (GP)As a matter of courtesy and in the interest of your wellbeing, we may let your GP know about your participation in the study, and may request your permission to send them a letter when you enroll. If you agree to this, you will be asked to provide us with your GP’s contact details so that we can send them a letter with details of the research.  
Insurance/indemnityStandard KCL insurance and NHS indemnity arrangements apply.
Involvement of the insurance companyIf you have private medical insurance, you should inform your insurance company that you are taking part in this study. 
Will any genetic tests be done?No. 
What will happen to the results of the research study?
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You will be offered the opportunity to be informed about your individual results once the data for all participants has been collected. If you want written feedback of the study’s findings you can contact the researcher (gemma.gordon@kcl.ac.uk) for a lay summary. The results will be included in an examined postgraduate report, presented as part of a postgraduate presentation, and sent to a medical journal for publication. Your participation in the study will not be disclosed.
Who is organising and funding the research?This study is being funded by King’s College London. 
Who has reviewed the study?All research in the NHS is looked at by an independent group of people, called a Research Ethics Committee, to protect your interests. This study has been reviewed and given favourable opinion by North West -Liverpool East Research Ethics Committee.
Further information and contact detailsIf you have any questions or require more information about this study, please contact the researcher using the following contact details: Gemma Gordon (gemma.gordon@kcl.ac.uk) (0207 848 5608)Section of Eating Disorders, Department of Psychological MedicineKCL Institute of Psychiatry, Psychology and Neuroscience,16 De Crespigny ParkLondon, SE5 8AF
Appendix B: Consent form for all participants
CONSENT FORM 
IRAS Project ID: 244170
Research Ethics Committee reference number: 18/NW/0648
Please complete this form after you have read the information 
sheet and listened to an explanation about the research.
Title of Study: ICARUS - An Investigation of Approach Bias 
Modification Training (ABM) and Transcranial Direct Current 
Stimulation (tDCS) in Binge Eating Disorder
Name of Researcher: Gemma Gordon
Thank you for considering taking part in this research. The 
person organising the research must explain the project to you before you 
agree to take part.  If you have any questions arising from the information 
sheet or explanation already given to you, please ask the researcher before you 
decide whether to join in. You will be given a copy of this consent form to keep 
and refer to at any time.
Please initial box
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1.    I confirm that I have read the information sheet dated 18.09.2018 (version 3) for 
the above study. I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily.
2. I understand that my participation is voluntary and that I am free to withdraw 
at any time without giving a reason, without my medical care or legal rights 
being affected.  
3. I consent to the processing of my personal information for the purposes 
explained to me. I understand that such information will be handled in 
accordance with the terms of the General Data Protection Regulation (GDPR) 
2018. I understand that confidentiality and anonymity will be maintained and 
it will not be possible to identify me in any publications.
4. I know that if I would like to, I can contact the research team and request a written               
summary of the study findings.
5. I understand that I must not take part if I have any of the conditions listed in 
the exclusion criteria.
6. I understand that during study participation, I must inform the researcher of 
any changes in my medication or of any new medical diagnoses made.
7. I agree to my General Practitioner (GP) being informed of my participation in 
this study.
8. I consent/do not consent to be contacted in the future by King’s College London            
researchers who would like to invite me to participate in follow up studies to this 
project, or in future studies of a similar nature. 
9. I agree to take part in the above study.
Participant’s Statement:
I _____________________________________________________________________
agree that the research project named above has been explained to me to my satisfaction 
and I agree to take part in the study. I have read both the notes written above and the 
Information Sheet about the project, and understand what the research study involves.
Signed Date
Investigator’s Statement:
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I ______________________________________________________________________
Confirm that I have carefully explained the nature, demands and any foreseeable risks (where 
applicable) of the proposed research to the participant.
Signed                                          Date
For administration purposes, please indicate your preference below
Q: In what format would you like to complete the at-home assessment questionnaires?
Tick  ‘ ‘  in one box to indicate your choice
1.  I would like to complete the assessment questionnaires online
2. I would like to receive a hardcopy paper version of the questionnaires in a 
    stamped addressed envelope, to complete and post back to the researcher within 
36 hours of the in-person assessment visit.
Enquiries:
Gemma Gordon (gemma.gordon@kcl.ac.uk)
Department of Psychological Medicine
Section of Eating Disorders
KCL Institute of Psychology, Psychiatry and Neuroscience,
16 De Crespigny Park
London, SE5 8AF
Phone: 0207 848 5608
Appendix C: ICARUS study task, questionnaire, measure and scale information
(1) Approach bias assessment tasks
(i) Food Approach-Avoidance Task (F-AAT) (Rinck & Becker, 2007): The F-AAT is a 
computerised task that measures approach and avoidance behaviour by means of joystick 
movements in response to food and neutral stimuli presented on a computer screen. This 
task will be used to assess approach bias towards visual cues of high-calorie food (expected 
target cognitive mechanism of intervention). Images of palatable edible foods (i.e. 
chocolate, pizza) and non-edible objects (i.e. sponges, stapler) are used as in previously 
(Brockmeyer et al., 2019). The assessment version of the AAT is identical to the treatment 
version except that the required response is unrelated to the picture content (i.e. food and 
neutral stimuli are presented equally often in round and rectangular, i.e. push and pull, 
format). Format movement assignments are counterbalanced among participants (i.e., half 
push round pictures and half push rectangular pictures). When the joystick is pulled, the 
picture grows bigger, and diminishes in size when the joystick is pushed. Zooming-in and 
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zooming-out via joystick movements enacts motions of approaching and avoiding 
respectively and thus combines the proprioceptive (arm movement) and exteroceptive 
(zooming feature) cues of approach and avoidance behaviour (Neumann & Strack, 2000; 
Brockmeyer et al., 2019). The assessment version of the AAT consists of 80 trials (40 food 
item pictures and 40 non-food item pictures). To evaluate approach bias towards food, a 
compatibility score is calculated by subtracting the median reaction times (RTs) of 
compatible trials (i.e., RT pull food + RT push nonfood) from median RTs of incompatible 
trials (i.e., RT push food + RT pull nonfood) (Brockmeyer et al., 2019; Becker et al., 2016; 
Vrijsen et al., 2018). A positive value indicates a food-specific approach bias (i.e. the 
participant is faster at pulling than pushing food pictures, relative to the approach bias 
towards non-food), whereas a negative value indicates an avoidance bias. This task will be 
performed using Inquisit 5 (Millisecond Software).
(ii) The Stimulus Response Compatibility Task (SRC) (De Houwer, Crombez, Baeyens, & 
Hermans, 2001): In this task, participants respond to images on a computer screen by 
pressing keys on the keyboard. Pictures are presented in the centre of the screen with a 
manikin (12 mm high) positioned 33 mm above or below the picture. Participants are 
required to categorise the presented pictures by making an approach response (pressing the 
up or down key to move the manikin toward the picture) or an avoidance response (pressing 
the up or down key to move the manikin away from the picture). After making a correct 
response, an animation is shown of the manikin walking toward the picture (approach) or 
away from the picture (avoidance) for 1,000 ms. After making an incorrect response, a red 
cross appears on the screen for 500 ms, after which the next trial starts. Fourteen food and 
fourteen non-food pictures will be used from the food-pics database (Blechert, Meule, 
Busch & Ohla, 2014). The experiment comprises 8 practice trials and 56 experimental trials. 
Bias scores will be calculated by subtracting the mean of approach food/avoid non-food 
trials from the mean of avoid food/approach non-food trials. A positive
score indicates a food-related approach bias, with higher scores indicative of stronger 
biases. This task will be performed using Inquisit 5 (Millisecond Software).
(2) Food Choice Task 
The Food Choice Task (Hare, Camerer & Rangel., 2009) adapted for eating disorders 
(Steinglass et al., 2015) is a computer-based paradigm that measures responses to images of 
foods to assess food attitudes and characteristics of eating behaviour. Food stimuli is used 
to investigate how individuals make decisions about what to eat, and measures decision-
making around food by directly probing personal preferences. There are no learning 
requirements and individualised assessments of food along two dimensions (healthiness 
and tastiness) allow the tasks to be used in diverse populations with differing valuations of 
food. The task consists of three phases. In each phase participants are presented with 43 
images of food items. The food items represent an array of dietary options (Steinglass et al., 
2015). Twenty-five food items are low fat (<30% calories from fat) and 18 are high fat (>30% 
calories from fat), as determined by Foerde et al. (2018). In the Health phase, participants 
rate the healthiness of each food item on a 5-point scale (1 = “Unhealthy”, 5 = “Healthy”). In 
the Taste phase, participants rate the tastiness of each food item in a similar fashion, (1 = 
“Bad”, 5 = “Good”). In the Choice phase, in each trial participants choose between the 
presented food item and a “Neutral” reference food item (rated as 3 in both Health and 
Taste phases). If no item is rated 3 on both scales, an item rated 3 on Health and greater 
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than 3 on the Taste scale is selected as a reference food. Good test-retest reliability of the 
FCT suggests that it is suitable for measuring food-based decision-making in studies with 
multiple assessment points (Foerde et al., 2018).
(3) State food craving - Food craving after cue exposure task
The Food Challenge Task (FCT) (Kekic et al., 2017; Meule et al., 2018) will be used to 
examine cue-induced food craving. In this task, participants rate their state food craving 
using the Food Cravings Questionnaire State Version (Cepeda-Benito et al., 2000; Meule et 
al., 2012) before and after being presented with a video on a computer screen of foods 
shown to be highly appetitising and to elevate hunger levels (Kekic et al., 2017). The 
questionnaire consists of 15 items that measure the strength of food cravings (i.e. I would 
feel more alert if I could satisfy my craving). Participants are asked to indicate how much 
they agree with each statement ‘at this very moment’ using a five-point scale (from 1 
‘strongly disagree’ to 5 ‘strongly agree’). There are five craving subscales; intense desire to 
eat, anticipation of relief from negative states, physiological craving, preoccupation with 
food or lack of control over eating and anticipation of positive reinforcement. Scores can be 
calculated for specific subscales or a total score can be calculated (ranging from 15 to 75). 
This questionnaires will be completed using Inquisit 5 (Millisecond Software), and the video 
shown using QuickTime player.
(4) Trait food craving
The Yale Food Addiction Scale Version 2.0 (YFAS 2.0; Gearhardt, Corbin, & Brownell, 2016) is 
the most commonly used instrument to assess food-related addictive behaviours (Steward 
et al., 2018). This self-report questionnaire consists of 35 items scored on an 8-point Likert 
scale (from 0 = never to 7 = every day) and is adapted to assess addictive eating behaviours 
based on DSM-5 substance-related and addictive disorders criteria (APA, 2013). It refers 
specifically to consumption of foods high in fat, sugar, salt or refined carbohydrates. It 
includes items that assess specific criteria, such as diminished control over consumption, a 
persistent desire or repeated unsuccessful attempts to quit, withdrawal, and clinically 
significant impairment (i.e. ‘I kept eating in the same way even though my eating caused 
emotional problems’). The YFAS includes two scoring options: 1) a “symptom count” ranging 
from 0 to 7 that reflects the number of addiction-like criteria endorsed and 2) a categorical 
scoring option that classifies respondents as having either no, mild, moderate or severe 
‘food addiction’. The YFAS has received psychometric support in binge eating populations 
(Gearhardt, White et al., 2013; Carter, Van Wijk & Rowsell, 2019), and obese bariatric 
surgery patients (Clark & Saules, 2013; Meule, Heckel, & Kübler, 2012). The YFAS 2.0 was 
developed to maintain consistency with the current diagnostic understanding of addiction 
and to improve the psychometric properties of the original YFAS. Exceeding the food 
addiction threshold was more strongly associated with obesity for the YFAS 2.0 than the 
original YFAS. The YFAS 2.0 has demonstrated good internal consistency (Carter, Van Wijk & 
Rowsell, 2019), as well as convergent, discriminant and incremental validity (Gearhardt, 
Corbin & Brownell, 2016).
(5) Food intake in a Bogus Taste Test
Actual food consumption will be measured by means of a Bogus Taste Test (Robinson et al., 
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2017); a food consumption test presented under the guise of a taste test. Participants will 
be instructed to rate 3 bowls of highly palatable high-calorie food items (chocolate, sweets, 
crisps) in terms of their visual attractiveness, smell, and taste on a paper form. The 
researcher will inform the participant that she/he will leave the room for 10 minutes and 
during this time they can complete their ratings and are free to eat as much of the offered 
items as they like. A small bin with lid will be provided and participants will be instructed to 
consume as much food as they need or want, and to discard the remainder of the food 
items in the bin before 10 minutes are over. After the participant has left, the discarded 
food items will be recovered from the bin, sorted, and placed in their original bowls. 
Consumption will be determined by weighing the bowls both before and after the “taste 
test” and the difference in weight from pre-to post-assessment will be converted into 
calories and used as a measure of food intake. 
(6) Delay discounting 
Delay Discounting Task with Money and Food (Odum, Baumann, & Rimington, 2006): 
Participants indicate their preferences in a series of choices for two hypothetical outcome 
types: immediate versus delayed food and immediate versus delayed money. Participants 
make choices involving either relatively small maximum amounts of food (10 dollars worth) 
and money (10 dollars) or for relatively large maximum amounts of food (100 dollars worth) 
and money (100 dollars). Performance on this task can be used to study self-regulation, 
delayed gratification and valuation of reward. This task will be performed using Inquisit 5 
(Millisecond Software).
(7) Inhibitory control 
(i) Go/No-Go task: The cued go/no go task is a useful measure of impulse control in clinical 
populations. This task is a classic test of executive function, requiring effortful response 
inhibition. The food specific version of the cued go no-go task (Teslovich et al., 2014) 
measures impulsivity and response inhibition with respect to appetising food and nonfood 
items (i.e. toys), via assessing the ability to inhibit instigated, prepotent responses. The task 
manipulates response prepotency by presenting a preliminary go or no-go cue before the 
actual go or no-go target is displayed. The cues provide information concerning the 
probability that a go or no-go target will be presented. The cue-target relationship is 
manipulated so that the cues have a high probability of correctly signaling a go or no-go 
target (valid cues), and a low probability of incorrectly signaling a target (invalid cues). Valid 
cues tend to facilitate response inhibition and speed response execution, whereas invalid 
cue cues tend to impair response inhibition and slow response execution. The set of stimuli 
consists of 30 colour images of common high- (8) and low-calorie (7) foods and common 
toys (15). The outcome variables include: (1) overall reaction time (RT) in milliseconds 
during correct “go” trials, (2) rate of omission errors (missed “go” trials), and (3) false alarm 
rate (rate at which participants erroneously press to a no-go stimulus). This task will be 
performed using Inquisit 5 (Millisecond Software).
(i) Stop Signal Task (SST): This is a task measuring inhibitory control. Participants are 
required to engage in a computer task but withhold their response in the presence of a stop 
signal. This SST includes food-specific and neutral non-food stimuli in the same task 
(adaptation of Manasse et al., 2016). This allows for isolation of any unique food specific 
inhibitory control deficits from general difficulties inhibiting responses. The outcome 
measure is the stop signal reaction time (SSRT). The SSRT is calculated for each set of stimuli 
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(i.e., SSRT stimulus type) for each subject by subtracting the average stop signal delay from 
the average reaction time on “go” trials (Verbruggen & Logan, 2008). The recording 
accuracy of reaction time and stop signal delay measurement is in milliseconds. A smaller 
SSRT is indicative of greater inhibitory control and a larger SSRT reflects weaker/impaired 
inhibitory control. This task will be performed using Inquisit 5 (Millisecond Software).
(8) Mood and emotion regulation
The Emotion Regulation Questionnaire (ERQ) (Gross & John, 2003): A 10-item scale designed 
to measure respondents’ tendency to regulate their emotions in two ways: (1) cognitive 
reappraisal and (2) expressive suppression. Respondents answer each item on a 7-point 
Likert-type scale ranging from 1 (strongly disagree) to 7 (strongly agree). This will be 
administered at pre-assessment, post-assessment and follow-up.
Positive and Negative Affect Schedule (PANAS) (Watson, Clarke & Tellegen, 1988): The 
PANAS consists of two 10-item self-report scales which measure positive and negative 
affect. On a Likert scale ranging from 0 (very slightly or not at all) to 4 (extremely), 
participants rate the extent to which they have experienced each of the 20 descriptors 
within a particular time frame (“right now” in the current study). Two scores are generated: 
positive (PANAS-positive) and negative (PANAS- negative) affect. This will be administered 
at pre-assessment, post-assessment and follow-up. 
Depression, Anxiety and Stress Scale (21-item version; DASS-21) (Lovibond & Lovibond, 
1995): This is a 21 item self-report questionnaire which aims to evaluate mood, anxiety and 
stress levels over the previous week. The DASS-21 will be administered at pre-assessment, 
post-assessment and follow-up. 
(9) Within session measures (immediately after each [ABM+real/sham tDCS] treatment 
session)
(i) Paper-based Visual Analogue Scales (VAS) assessing current hunger, feeling of fullness, 
urge to eat, urge to binge eat, feeling low, level of tension, level of stress, level of anxiety. 
These scales consist of a 10cm line. Participants are requested to indicate on this line a 
degree or level of a specific emotion or behavioural urge. There are indications of what 
range (e.g. from 'not at all' to 'extremely'). 
(ii) Tolerance, discomfort and side effects: An evaluation of discomfort with the training 
session (tDCS and ABM aspects separately) will be completed with another paper-based 
10cm VAS (rated from none to extreme discomfort). Participants will be asked to report any 
side effects in an open ended question.
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SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents* 
Section/item Item 
No 
Description Addressed on 
page number 
Administrative information 
 
Title 1 Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym _______1______ 
Trial registration 2a Trial identifier and registry name. If not yet registered, name of intended registry _______1______ 
2b All items from the World Health Organization Trial Registration Data Set _____________ 
Protocol version 3 Date and version identifier ______1_______ 
Funding 4 Sources and types of financial, material, and other support ______12_______ 
Roles and 
responsibilities 
5a Names, affiliations, and roles of protocol contributors ______12______ 
5b Name and contact information for the trial sponsor ______12_______ 
 5c Role of study sponsor and funders, if any, in study design; collection, management, analysis, and 
interpretation of data; writing of the report; and the decision to submit the report for publication, including 
whether they will have ultimate authority over any of these activities 
 
______12______ 
 5d Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint 
adjudication committee, data management team, and other individuals or groups overseeing the trial, if 
applicable (see Item 21a for data monitoring committee) 
 
 
 
_____11____ 
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Introduction 
   
Background and 
rationale 
6a Description of research question and justification for undertaking the trial, including summary of relevant 
studies (published and unpublished) examining benefits and harms for each intervention 
_____2-4___ 
 6b Explanation for choice of comparators ______4__ 
Objectives 7 Specific objectives or hypotheses ______4___ 
Trial design 8 Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), 
allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory) 
 
______5______ 
Methods: Participants, interventions, and outcomes  
Study setting 9 Description of study settings (eg, community clinic, academic hospital) and list of countries where data will 
be collected. Reference to where list of study sites can be obtained 
_____6_____ 
Eligibility criteria 10 Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and 
individuals who will perform the interventions (eg, surgeons, psychotherapists) 
______5_____ 
Interventions 11a Interventions for each group with sufficient detail to allow replication, including how and when they will be 
administered 
____9-10___ 
11b Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose 
change in response to harms, participant request, or improving/worsening disease) 
____11___ 
11c Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence 
(eg, drug tablet return, laboratory tests) 
  ____11____ 
11d Relevant concomitant care and interventions that are permitted or prohibited during the trial ____4, 11___ 
Outcomes 12 Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood 
pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, 
median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen 
efficacy and harm outcomes is strongly recommended 
 
____6-9___ 
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Participant timeline 13 Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for 
participants. A schematic diagram is highly recommended (see Figure) 
___6__ 
Sample size 14 Estimated number of participants needed to achieve study objectives and how it was determined, including 
clinical and statistical assumptions supporting any sample size calculations 
____5___ 
Recruitment 15 Strategies for achieving adequate participant enrolment to reach target sample size ___11__ 
Methods: Assignment of interventions (for controlled trials) 
 
Allocation:    
Sequence 
generation 
16a Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any 
factors for stratification. To reduce predictability of a random sequence, details of any planned restriction 
(eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants 
or assign interventions 
____5-6___ 
Allocation 
concealment 
mechanism 
16b Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, 
opaque, sealed envelopes), describing any st ps to conceal the sequence until interventions are assigned 
____6___ 
Implementation 16c Who will generate the allocation sequence, who will enrol participants, and who will assign participants to 
interventions 
____5____ 
Blinding (masking) 17a Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome 
assessors, data analysts), and how 
___5____ 
 17b If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant’s 
allocated intervention during the trial 
___6____ 
Methods: Data collection, management, and analysis 
 
Data collection 
methods 
18a Plans for assessment and collection of outcome, baseline, and other trial data, including any related 
processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of 
study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. 
Reference to where data collection forms can be found, if not in the protocol 
____6-8____ 
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 18b Plans to promote participant retention and complete follow-up, including list of any outcome data to be 
collected for participants who discontinue or deviate from intervention protocols 
_____10-11____ 
Data management 19 Plans for data entry, coding, security, and storage, including any related processes to promote data quality 
(eg, double data entry; range checks for data values). Reference to where details of data management 
procedures can be found, if not in the protocol 
_____10-11_____ 
Statistical methods 20a Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the 
statistical analysis plan can be found, if not in the protocol 
_____10_____ 
 20b Methods for any additional analyses (eg, subgroup and adjusted analyses) _____10______ 
 20c Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any 
statistical methods to handle missing data (eg, multiple imputation) 
 
______10______ 
Methods: Monitoring 
 
Data monitoring 21a Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of 
whether it is independent from the sponsor and competing interests; and reference to where further details 
about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not 
needed 
_____10_____ 
 21b Description of any interim analyses and stopping guidelines, including who will have access to these interim 
results and make the final decision to terminate the trial 
_____11______ 
Harms 22 Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse 
events and other unintended effects of trial interventions or trial conduct 
_____11_____ 
Auditing 23 Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent 
from investigators and the sponsor 
_______n/a____ 
Ethics and dissemination  
Research ethics 
approval 
24 Plans for seeking research ethics committee/institutional review board (REC/IRB) approval ______1, 13____ 
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Protocol 
amendments 
25 Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, 
analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, 
regulators) 
_____1, 12_____ 
Consent or assent 26a Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and 
how (see Item 32) 
_____12_____ 
 26b Additional consent provisions for collection and use of participant data and biological specimens in ancillary 
studies, if applicable 
_____n/a_____ 
Confidentiality 27 How personal information about potential and enrolled participants will be collected, shared, and maintained 
in order to protect confidentiality before, during, and after the trial 
____10-11____ 
Declaration of 
interests 
28 Financial and other competing interests for principal investigators for the overall trial and each study site _____12______ 
Access to data 29 Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that 
limit such access for investigators 
_____ 10_____ 
Ancillary and post-
trial care 
30 Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial 
participation 
______11_____ 
Dissemination policy 31a Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, 
the public, and other relevant groups (eg, via publication, reporting in results databases, or other data 
sharing arrangements), including any publication restrictions 
______1, 11_____ 
 31b Authorship eligibility guidelines and any intended use of professional writers ______12______ 
 31c Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code ______n/a______ 
Appendices 
   
Informed consent 
materials 
32 Model consent form and other related documentation given to participants and authorised surrogates ______24______ 
Biological 
specimens 
33 Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular 
analysis in the current trial and for future use in ancillary studies, if applicable 
______n/a______ 
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*It is strongly recommended that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarification on the items. 
Amendments to the protocol should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Commons 
“Attribution-NonCommercial-NoDerivs 3.0 Unported” license. 
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CONSORT 2010 checklist  Page 1 
CONSORT 2010 checklist of information to include when reporting a randomised trial* 
 
Section/Topic 
Item 
No Checklist item 
Reported 
on page No 
Title and abstract 
 1a Identification as a randomised trial in the title 1 
1b Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts) 1(no results) 
Introduction 
Background and 
objectives 
2a Scientific background and explanation of rationale 2-4 
2b Specific objectives or hypotheses 4-5 
Methods 
Trial design 3a Description of trial design (such as parallel, factorial) including allocation ratio 5 
3b Important changes to methods after trial commencement (such as eligibility criteria), with reasons n/a 
Participants 4a Eligibility criteria for participants 5 
4b Settings and locations where the data were collected 6 
Interventions 5 The interventions for each group with sufficient details to allow replication, including how and when they were 
actually administered 
9-10 
Outcomes 6a Completely defined pre-specified primary and secondary outcome measures, including how and when they 
were assessed 
6-9 
6b Any changes to trial outcomes after the trial commenced, with reasons n/a 
Sample size 7a How sample size was determined 5 
7b When applicable, explanation of any interim analyses and stopping guidelines 11 
Randomisation:    
 Sequence 
generation 
8a Method used to generate the random allocation sequence 5-6 
8b Type of randomisation; details of any restriction (such as blocking and block size) 5-6 
 Allocation 
concealment 
mechanism 
9 Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), 
describing any steps taken to conceal the sequence until interventions were assigned 
6 
 Implementation 10 Who generated the random allocation sequence, who enrolled participants, and who assigned participants to 
interventions 
5 
Blinding 11a If done, who was blinded after assignment to interventions (for example, participants, care providers, those 5 
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CONSORT 2010 checklist  Page 2 
assessing outcomes) and how 
11b If relevant, description of the similarity of interventions 4 
Statistical methods 12a Statistical methods used to compare groups for primary and secondary outcomes 10 
12b Methods for additional analyses, such as subgroup analyses and adjusted analyses 10 
Results 
Participant flow (a 
diagram is strongly 
recommended) 
13a For each group, the numbers of participants who were randomly assigned, received intended treatment, and 
were analysed for the primary outcome 
n/a 
13b For each group, losses and exclusions after randomisation, together with reasons n/a 
Recruitment 14a Dates defining the periods of recruitment and follow-up n/a 
14b Why the trial ended or was stopped n/a 
Baseline data 15 A table showing baseline demographic and clinical characteristics for each group n/a 
Numbers analysed 16 For each group, number of participants (denominator) included in each analysis and whether the analysis was 
by original assigned groups 
n/a 
Outcomes and 
estimation 
17a For each primary and secondary outcome, results for each group, and the estimated effect size and its 
precision (such as 95% confidence interval) 
n/a 
17b For binary outcomes, presentation of both absolute and relative effect sizes is recommended n/a 
Ancillary analyses 18 Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing 
pre-specified from exploratory 
n/a 
Harms 19 All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) n/a 
Discussion 
Limitations 20 Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses n/a 
Generalisability 21 Generalisability (external validity, applicability) of the trial findings n/a 
Interpretation 22 Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence n/a 
Other information  
Registration 23 Registration number and name of trial registry 1 
Protocol 24 Where the full trial protocol can be accessed, if available n/a 
Funding 25 Sources of funding and other support (such as supply of drugs), role of funders 12 
 
*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also 
recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials. 
Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see www.consort-statement.org. 
Page 49 of 76
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
07.07.2019 V1
Combining cognitive bias modification training (CBM) and transcranial direct 
current stimulation (tDCS) to treat binge eating disorder: study protocol of a 
randomised controlled feasibility trial
Gemma Gordon1, Timo Brockmeyer2, Ulrike Schmidt1, Iain Campbell1
1Section of Eating Disorders, Department of Psychological Medicine, Institute of Psychiatry, 
Psychology and Neuroscience, King’s College London, London, United Kingdom
2Department of Clinical Psychology and Psychotherapy, Institute of Psychology, University of 
Goettingen, Goettingen, Germany
Correspondence: Gemma Gordon, Section of Eating Disorders, Department of Psychological 
Medicine, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, 
United Kingdom; E-mail: gemma.gordon@kcl.ac.uk
Key words: cognitive bias modification, transcranial direct current stimulation, eating disorders, 
binge eating, treatment
Word count (abstract): 290 Word count (manuscript): 5,908
Page 50 of 76
For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml
BMJ Open
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For peer review only
2
ABSTRACT
Introduction: Binge Eating Disorder (BED) is a common mental disorder, closely associated with 
obesity. Existing treatments are only moderately effective with high relapse rates, necessitating 
novel interventions. This paper describes the rationale for, and protocol of, a feasibility randomised 
controlled trial (RCT), evaluating the combination of transcranial Direct Current Stimulation (tDCS) 
and a computerised cognitive training, namely Approach Bias Modification training (ABM), in 
patients with Binge Eating Disorder who are overweight or obese. The aim of this trial is to obtain 
information that will guide decision making and protocol development in relation to a future large-
scale RCT of combined tDCS + ABM treatment in this group of patients, and also to assess the 
preliminary efficacy of this intervention. Methods and analysis:  66 participants with DSM-5 
diagnosis of BED and a body mass index (BMI) of >25 kg/m2 will be randomly allocated to one of 3 
groups: ABM + real tDCS; ABM + sham tDCS or a waitlist control group. Participants in both 
intervention groups will receive 6 sessions of ABM + real/sham tDCS over 3 weeks; engaging in the 
ABM task while simultaneously receiving bilateral tDCS to the dorsolateral prefrontal cortex. ABM is 
based on an implicit learning paradigm in which participants are trained to enact an avoidance 
behaviour in response to visual food cues. Assessments will be conducted at baseline, post-
treatment (3 weeks), and follow-up (7 weeks post-randomisation). Feasibility outcomes assess 
recruitment and retention rates, acceptability of random allocation, blinding success (allocation 
concealment), completion of treatment sessions and research assessments. Other outcomes include 
eating disorder psychopathology and related neurocognitive outcomes (i.e. delay of gratification and 
inhibitory control), BMI, other psychopathology (i.e. mood), approach bias towards food, and 
surrogate endpoints (i.e. food cue reactivity, trait food craving, and food intake).
Ethics and dissemination: This study has been approved by the North West - Liverpool East Research 
Ethics Committee. Results will be published in peer-reviewed journals.
Trial registration number: ISRCTN35717198
Strengths and limitations of this study
 The ICARUS study is the first randomised controlled feasibility trial of multi-session 
transcranial Direct Current Stimulation (tDCS) combined with Cognitive Bias Modification 
training (CBM) for adults with Binge Eating Disorder.
 ICARUS will compare [tDCS + CBM] vs. [sham tDCS + CBM] and a wait-list control group.
 ICARUS is designed to answer questions about the efficacy of the treatments tested.
 Results would need to be replicated in a larger trial before recommendations for tDCS + 
CBM as a treatment adjunct for patients receiving outpatient treatment for BED can be 
made.
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INTRODUCTION
Binge Eating Disorder (BED) is the most prevalent eating disorder (ED) worldwide, with 1-3% of the 
general population meeting diagnostic criteria[1,2]. Binge eating is a core symptom, characterised by 
consumption of large amounts of food, a sense of loss of control, and significant distress. Nearly 80% 
of those with lifetime BED have a comorbid psychiatric disorder, such as mood, anxiety, substance 
use disorders or another ED[2]. Due to the lack of compensatory behaviours (e.g. vomiting, excessive 
exercising), BED is often accompanied by, or leads to, obesity and associated physical 
complications[3,4]. In the general population, approximately 30-42% of people with BED are 
obese[2,5,6]. Around 30% of treatment-seeking obese people[7–9] and up to 47% of bariatric 
surgery candidates have full or partial BED[1,10,11]. Whilst BED itself has considerable individual and 
societal costs[12], the combination of BED and obesity is associated with more severe obesity, 
greater medical and psychiatric comorbidity, greater functional impairment and perinatal 
complications[12–15]. Treatments for BED and obesity are sub-optimally effective, with cognitive 
behavioural therapy (CBT) and some medications reducing binge eating and related 
psychopathology[1], and approximately 50-60% of patients achieving abstinence from bingeing at 
the end of treatment[18] with some sustained cessation at follow-up[19]. However, drop-out rates 
in established BED treatments reach 12-34%, and 30%-50% of BED patients relapse in long-term 
follow-ups[20–22], indicating that a substantial proportion do not maintain binge eating remission. 
Lisdexamfetamine[23] and topiramate[24] also reduce weight in the short-term but have 
considerable side effects[25], and their longer term efficacy is uncertain. Thus, there is a need for 
novel treatment developments.  
The aetiology of BED is widely seen as multi-factorial. Emerging neurobiological models emphasise 
both the role of stress in the onset and maintenance of the disorder[26,27], and the development of 
addiction-like features; craving, tolerance and binge escalation over time[28,29], impulsivity and 
compulsivity, alterations in executive function and attention[30] and reward-related decision 
making[31]. 
Upon encountering images of high-calorie food, BED patients report enhanced reward sensitivity 
and exhibit stronger medial orbitofrontal cortex responses compared to healthy controls and 
participants with bulimia nervosa[32]. In individuals with obesity, who may or may not have BED, 
activation in the ventral striatum (part of the reward system) has been found to be higher compared 
to normal-weight controls [33], in tandem with a more pronounced approach bias towards 
appetising food images [34,35], leading to greater likelihood of consumption. Furthermore, poor 
reward-related decision making behaviour may be a maintaining factor in obesity[36]. Converging 
data using different methodologies, such as brain imaging, eye tracking, and behavioural test 
paradigms [37] have found that patients with BED demonstrate a higher arousal rate in response to 
food stimuli, a concurrent motor plan to start eating, a higher reward sensitivity, and greater 
inhibitory deficits as compared to individuals without BED[32,38,39]. Those with obesity and BED 
(compared to obesity alone) have demonstrated that their attentional bias to food images held 
higher motivational value[40], and responded more to high calorie food images in sites of cognitive 
planning of motor movements, driven by emotions, which may reflect impulsive tendencies in the 
face of a binge-eating trigger. This tendency to approach and consume palatable food items may 
thus be compounded by a greater sensitivity to reward and a decreased capacity to inhibit action 
tendencies. This is corroborated by the recent finding that individuals with BED or Bulimia Nervosa 
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(BN) show higher food cue reactivity (increased cravings) when exposed to visual food cues 
compared to healthy controls [41]. Such accumulating evidence of BED as a unique diagnostic group 
situates it as a distinct phenotype within the obesity spectrum that is characterised by increased 
impulsivity [42].
Conventional treatments of BED, such as CBT may not be best suited to target highly automatic 
cognitive processes that occur at an early stage in information processing and that are considered to 
contribute to food craving and associated maladaptive cognitions/behaviours. Two “brain-directed” 
treatments may provide an avenue for modifying these processes: Approach Bias Modification 
training (ABM) and transcranial Direct Current Stimulation (tDCS).
Approach Bias Modification training (ABM) is a form of cognitive bias modification training (CBM) 
that aims to retrain approach bias tendencies (reach out towards) into avoidance ones (move away 
from)[43] regarding stimuli such as appetitive cues. Participants are systematically trained to show 
an avoidance movement in response to illness-related rewarding stimuli (e.g. food or alcohol) on a 
computer screen. ABM techniques have shown potential in several pilot and large-scale randomised 
controlled studies to treat alcohol[44] and tobacco[45] addictions, and to reduce consumption of 
cannabis[46] and unhealthy foods[47,48]. ABM has also yielded promising results in people with high 
levels of food craving and in bulimic eating disorders, including BED[49,50]. However, mixed results 
in empirical studies across these domains[51,52] raise methodological issues of ABM studies to date, 
such as low statistical power and suboptimal choice (or absence) of control groups[53] and 
administration of single versus multiple training sessions.
Transcranial Direct Current Stimulation (tDCS) is a form of non-invasive brain stimulation (NIBS) that 
has been used as a treatment adjunct for a range of psychiatric disorders, such as depression, 
schizophrenia and addictions[54–56]. Preliminary evidence suggests that tDCS and other forms of 
non-invasive brain stimulation are promising tools to reduce food craving, ED symptoms and body 
weight in bulimic EDs, including BED, and obesity[57]. Additionally, some studies indicate that NIBS 
may reduce depression/stress levels and improve reward-based decision making in ED patients[58]. 
A frequent stimulation target is the dorsolateral prefrontal cortex (dlPFC) which plays a major role in 
cognitive-inhibition, emotion regulation, and reward processing[58–61]. Although precise 
mechanisms of action of tDCS have yet to be understood, a key hypothesis in relation to BED is that 
enhancing dlPFC activity via tDCS alters the reward-cognition balance towards facilitation of 
cognitive control and suppression of reward-related mechanisms driving food 
craving/overeating[62]. 
If given concurrently (i.e. ‘online training’), NIBS is reported to boost the effects of cognitive training 
on the reduction of cognitive biases and the improvement of response inhibition[63]. NIBS may 
enhance synaptic strength in neuronal pathways activated by cognitive training, amplifying effects of 
training, and thus cognitive bias modification efficacy [64]. As the effectiveness of tDCS may thus be 
improved by pairing administration with a cognitive task inducing activity in the target brain 
region[65–67], such combined treatment interventions have been investigated among alcohol 
dependent inpatients (ABM and tDCS)[68], and to enhance inhibitory control related to food 
consumption (Go/No-Go Task and tDCS)[65]. The insignificant findings from these studies warrant 
commentary that to date, studies that have found positive effects of tDCS have either included 
obese participants or have had multisession protocols[65,69–71]. As this study incorporates both 
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aspects, it is optimally designed to yield significant results.
 
In light of both the individual and societal burden incurred by the rising prevalence of BED and 
obesity, research interventions informing treatments that lead to stable and long-lasting remission 
are of critical importance, and novel therapies may play a role in serving as adjuncts to treatment as 
usual, to enhance improvement in clinical outcomes obtained from engaging with eating disorder 
treatment services.  This research trial is the first to combine two promising novel intervention 
strategies in an integrated treatment and will yield important findings to shape future clinical trials. 
The intervention conditions of this feasibility study will involve 6 sessions of concurrent ABM and 
real or sham tDCS over 3 weeks, and will assess participant acceptability and dropout rates at this 
treatment frequency and duration. Additionally, the frequency of participants’ ED symptoms and 
other outcomes related to general psychopathology and neurocognition will be measured before 
and after the study interventions to assess treatment success. In summary, this proof-of-concept 
and feasibility study will establish the utility of concurrent ABM + real tDCS in improving clinical 
outcomes in participants with BED, compared to ABM + sham tDCS, and a wait-list control group. 
STUDY AIMS 
In line with established recommendations for outcomes of feasibility trials[72], which at present are 
supported by the National Institute for Health Research, the primary aim is to assess the feasibility of 
using concurrent ABM + real tDCS compared to concurrent ABM + sham tDCS as a potential adjunct 
to treatment as usual (TAU) in this patient population, and acquire key information to inform the 
development of a large-scale randomised sham-controlled trial (RCT). 
The specific objectives of the proposed feasibility study are to:
1. Establish the feasibility of conducting a large-scale RCT of ABM + tDCS in patients with BED 
by assessing recruitment, attendance, and retention rates;
2. Determine the practicality of administering both ABM and tDCS simultaneously;
3. Determine the best instruments for measuring outcomes in a full trial by examining the 
quality, completeness, and variability in the data;
4. Estimate the treatment effect sizes and standard deviations for outcome measures to inform 
the sample size calculation for a large-scale RCT;
5. Evaluate whether the treatment is operating as it is designed by analysing process measures, 
such as within-session visual analogue scales (VAS) of key ED symptoms;
6. Determine whether patients with BED evaluate concurrent ABM + tDCS as acceptable and 
credible;
7. Obtain information about patients’ willingness to undergo random allocation to ABM paired 
with either real or sham tDCS administration, or the wait-list control condition.
A secondary aim is to investigate the potential efficacy of concurrent delivery of both forms of 
treatment on binge eating disorder.
This will involve evaluating if:
1. Concurrent sessions of ABM + real tDCS are superior to ABM + sham tDCS and to wait-list 
control in terms of frequency of objective binge eating episodes, food cue reactivity, food 
craving, food intake, eating disorder psychopathology and mood.
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2. Concurrent ABM + tDCS is superior to the two other conditions in having an effect on the 
targeted neurocognitive mechanism (approach bias for high calorie food) and related 
neurocognitive parameters (i.e. impulsivity, delayed gratification, emotional regulation).
3. Concurrent ABM and sham tDCS is superior to the waitlist control in eliciting therapeutic 
effects on the aforementioned clinical outcomes and neurocognitive mechanisms, yet 
demonstrates an efficacy level below that of concurrent ABM and real tDCS.
METHODS AND ANALYSIS
This study protocol has been written according to the SPIRIT statement (Standard Protocol Items for 
Randomised Trials)[73] and the CONSORT 2010 statement (Consolidated Standards of Reporting 
Trials)[72].
Study design 
The ICARUS trial (Investigating Concurrent Approach Bias Modification Training and Transcranial 
Direct Current Stimulation in Binge Eating Disorder) is an exploratory randomised controlled 
feasibility trial with three parallel treatment conditions; ABM + real tDCS, ABM + sham tDCS and 
wait-list control. All participants across the two intervention groups will receive a treatment protocol 
of 6 sessions of ABM + real/sham tDCS conducted over 3 weeks. The comparator groups of a wait-list 
control and ABM + sham tDCS are necessary to evaluate the potential effect of real versus sham 
tDCS in participants with BED.  The wait-list control group will be examined at the same time points 
to control for the possibility that improvements in the intervention groups are simply due to 
regression to the mean, spontaneous remission or other non-specific time effects. Any participants 
who are engaging in treatment for their ED will continue with TAU, and thus this selection of 
comparators is deemed acceptable. Within treatment session measures will involve visual analogues 
scales evaluating mood, stress and eating disorder symptoms. Assessments will be conducted 3 
times during the study; at baseline, post-treatment (week 3), and at follow-up (week 7). 
Participants
Inclusion criteria entail: (1) male and female community-dwelling adults (aged 18-70); (2) overweight 
or obese according to WHO criteria (BMI>25 kg/m2)[74]; (3) a diagnosis of full-syndrome or sub-
threshold Binge Eating Disorder according to the DSM-5[75]L; (4) fluency in English; (5) normal or 
corrected to normal vision .
Exclusion criteria entail: (1) all known contraindications to tDCS[76]; (2) pregnancy; (3) a current 
significant/unstable medical or psychiatric disorder needing acute treatment in its own right; (4) a 
lifetime diagnosis of substance dependence, psychosis, bipolar disorder or borderline personality 
disorder; (5) taking psychotropic medication other than a stable dosage of selective serotonin 
reuptake inhibitors (SSRI) for at least 14 days prior to study enrolment; (6) allergies to any of the 
foods presented in the study; (7) smoking >10 cigarettes per day; (8) drinking >3-4 units (men) or 2-3 
units (women) of alcohol per day. In line with the CONSORT guidelines[77,78], we will record the 
number and reasons for any participants we must exclude, or any who decline consent or withdraw 
from the study.
Sample size
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As ICARUS is a feasibility study, an a priori sample size calculation is not necessary. Rather, its aim is 
to provide effect sizes on which future large-scale studies can be powered. Total study sample sizes 
of n=24 to n=50 have been recommended for feasibility trials with a primary outcome measured on 
a continuous scale, mainly because estimates of the standard deviation for normally distributed 
variables tend to stabilise around this size[79,80]. We have chosen a target end study sample size of 
n=60, (i.e. exceeds the upper end recommended for feasibility trials). However, assuming the 
attrition to follow-up rate is a = 0.10 (as found in previous eating disorder trials [81,82]) and applying 
an attrition correction factor of 1/(1-a), we will recruit an actual sample size of 66, i.e., 22 
participants per group.
Randomisation 
After the baseline assessment, participants will be allocated to one of three conditions at random to 
receive 6 sessions of either concurrent ABM + real tDCS or ABM + sham tDCS, or no intervention in 
the wait-list control condition. As a proportion of participants recruited from an outpatient eating 
disorder clinic will be on a waiting list to receive treatment at the time of enrolment in this study and 
may commence treatment shortly after study enrolment, this study will not seek to balance groups 
in terms of therapy engagement or medication usage. Participants in the wait-list control group will 
be offered the opportunity to receive ABM + real tDCS after the end of the follow-up. Participants 
will be individually randomised on a 1:1:1 ratio to the intervention or control groups in equal 
numbers. The generation and implementation of the randomisation sequence will be conducted 
independently from the trial team through a randomisation administrator who is not involved in any 
recruitment or research activity related to the ICARUS study. Online randomisation software (Sealed 
Envelope, London, UK) will be used for this purpose. Upon participant enrolment, the researcher will 
contact the randomisation administrator, who will inform this researcher in charge of carrying out 
the intervention of the participant's allocation via phone or email. 
Blinding
Double blinding is implemented only for the intervention group cohorts of the trial. The research 
assessor will remain blind to each participant’s tDCS assignment within the two intervention 
conditions until after the participant has completed the follow-up assessment. This double blinding 
protocol will be ensured via administration of the tDCS (NeuroConn DC-STIMULATOR PLUS) using 
“study mode”. This involves a five-digit numerical code unique to each patient will be inputted into 
the device prior to the participant’s testing session, that will initialise either sham or real (active) 
stimulation. The tDCS administrator and participants will remain blind to tDCS stimulation type 
throughout the study. Set-up of the randomisation codes and programming of the tDCS device will 
be performed by an investigator not involved in the trial. To assess blinding success, each participant 
and the researcher will be asked to guess the treatment allocation at the end of the 6 treatment 
sessions and to indicate how certain they are of this guess. The study group allocation will be 
revealed to the participant after their follow-up assessment. In the event of a reported change in a 
participant’s medication, or a new clinical diagnosis made during their study participation, the early 
unblinding of study condition for an intervention group participant will be permissible. The trial 
database will be maintained ‘blind’ until the point of study data analyses.
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Recruitment
The study will take place at the Institute of Psychiatry, Psychology and Neuroscience (IoPPN), King’s 
College London (KCL), UK. Participants will be recruited from the Eating Disorders Service at the 
South London and Maudsley NHS Foundation Trust, from the KCL research recruitment webpage and 
social media account, and via posters placed on notice boards on KCL campuses. Participants who 
have previously taken part in research at the KCL Eating Disorders Unit and who have consented to 
be informed of future studies may also be contacted. The ICARUS study will also be advertised on 
the Beat (National Eating Disorders Association) website, callforparticipants.com and 
www.mqmentalhealth.org. Potential participants will receive written and verbal study information 
and will be screened for eligibility. Eligible participants will provide informed written consent for 
study participation as a prerequisite for enrolment (See Appendices A and B). 
Procedure 
Figure 1 illustrates the timeline of the study procedures. All participants will partake in assessments 
at each of the three measurement points; baseline, post-treatment, and follow-up. Each assessment 
will comprise of an in-person study visit with tasks and measures, and online/hardcopy 
questionnaires and scales to be completed at home by the participant within 36 hours following the 
study visit. Table 1 details the tasks and measures allocated to each assessment and training visit. 
After the baseline assessment, participants are randomised to one of 3 groups; (1) ABM + real tDCS, 
(2) ABM + sham tDCS, or a waitlist control group (CG). Participants allocated to an intervention 
group will be offered 6 sessions of ABM + real/sham tDCS across 3 weeks. All study participants may  
receive TAU e.g. if they are currently engaged in outpatient treatment for their ED. The control 
group will not receive any study intervention, and any participants receiving outpatient services 
treatment for their ED will continue TAU during this 3 week period. The post-treatment assessment 
will be conducted on all participants after the 6th (final) session of ABM + real/sham tDCS for the 
intervention groups, and 3 weeks after the baseline assessment for the control group. The follow-up 
assessment will be conducted 28 days after the end of treatment, i.e. 7 weeks post-randomisation. A 
follow-up period is included because, if the effects of the intervention result from increased 
neuroplasticity, behavioural changes may need time to emerge. Assessing the longevity of 
favourable clinical outcomes beyond the treatment period is also relevant to the objectives of this 
feasibility study. The researcher conducting the assessment and testing sessions will remain blind to 
the study condition of intervention group participants until the follow-up has been completed.
Outcome assessment
Measures of feasibility, safety and adherence will be collected throughout the study. Outcomes 
related to ED symptoms, general psychopathology and neurocognition will be measured before and 
after the study intervention to assess treatment success. Each assessment session will be split into 
an in-person visit and at-home component to accommodate time constraints and minimise 
disruption to task performance due to participant fatigue. The in-person assessment measures will 
take approximately 75 minutes to complete, and the online questionnaires will take approximately 
45 minutes.
Outcome Measures  
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Feasibility outcomes
As this is a feasibility study, an extensive range of outcome measures are included to help determine 
which are most sensitive to detecting a treatment effect. This will enable us to determine primary 
outcome(s) for a future large-scale RCT. However, based on previous research[49], the Eating 
Disorder Examination Questionnaire (EDE-Q) is anticipated to be a key outcome measure.
Intervention/service related outcomes
Feasibility outcomes include recruitment, attendance and retention rates, and acceptability of 
treatment by participants. Patients’ acceptance of study interventions will be assessed by measuring 
treatment dropout rates and via the treatment tolerance and acceptability questionnaires. An 
interview assessment of treatment experience will be conducted with 20 participants after the 
follow-up is completed. 10 participants from each intervention group will be invited to provide 
feedback on their initial expectations and experiences of the ABM + real/sham tDCS treatments, 
perceived strengths and weaknesses of the treatment they received, and suggestions for 
improvements in procedures. Interviews will be recorded, transcribed and analysed using thematic 
analysis. This will allow future studies to consider patients’ feedback in the development of research 
and clinical protocols of concurrent ABM and tDCS.
Clinical outcomes
Eating disorder and related psychopathology
(a) Eating Disorder Examination (EDE-Q)[83]: The EDE-Q is a widely used measure of eating-
disordered behaviour and is widely regarded as the instrument of choice for the assessment of EDs. 
This will be administered at baseline, post-assessment and follow-up.
b) Body Mass Index (BMI (kg/m2)): This assessment of body composition provides accurate 
estimates of body fat percentages in adults, where sex and age are factored into the analysis 
measuring height and weight[84]. To calculate BMI, height and weight measurements will be 
obtained by the researcher at baseline, post-assessment and follow-up.
(c) Approach bias assessment tasks
To identify the most sensitive method of assessing change in approach bias towards high-calorie 
food items, two different computerised measures of approach bias will be used. In the Food 
Approach-Avoidance Task (F-AAT)[85] participants are shown colour photographs of high-calorie, 
palatable foods such as chocolate, cake, and pizza, and non-food household and office items such as 
sponges and stationary on a computer-screen[86]. They are instructed to approach and avoid these 
stimuli by moving a joystick toward themselves (approach) or away from themselves (avoidance). In 
the Stimulus Response Compatibility Task (SRC)[87], participants perform a symbolic movement by 
making a manikin image walk toward (approach) or away from stimuli (avoidance). See Appendix C 
for more detailed information. Both of these tasks will be administered at baseline, post-assessment 
and follow-up.
(d) Food choice attitudes/behaviour
The Food Choice Task[88–90] is a computer-based paradigm that measures responses to images of 
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foods to assess food attitudes and characteristics of eating behaviour. Participants rate images of 
food on a computer screen according to healthiness as well as tastiness. Based on these ratings they 
are then offered a choice between a food that they consider “neutral” and a series of other foods. 
See Appendix C for more detailed information. This task will be performed at baseline and post-
assessment.
(e) Food craving after cue exposure task
The Food Challenge Task (FCT)[41] will be used to examine cue-induced food craving. In this task, 
participants rate their state food craving using the Food Cravings Questionnaire State Version[91,92]  
before and after being presented with a video on a computer screen of foods shown to be highly 
appetising[93]. See Appendix C for more detailed information. This task will be performed at 
baseline and post-assessment.
(f) Trait food craving
Three questionnaires will be used to comprehensively assess mechanisms implicated in trait food 
craving. The Food Cravings Questionnaire Trait Version - reduced (FCQ-T-r)[94] is a 15 items only 
reduced version of a self-report questionnaire that measures trait levels of craving for food. The 21-
item Power of Food Scale (PFS)[95] scale assesses the psychological influence of the mere presence 
or availability of food. It measures appetite for, rather than consumption of, palatable foods, at 
three levels of food proximity (food available, food present, and food tasted). The Yale Food 
Addiction Scale Version 2.0 (YFAS 2.0)[96] reflects the current diagnostic understanding of addiction 
to further investigate the potential role of an addictive process in problematic eating 
behaviour[75,97–101]. See Appendix C for more detailed information. Each of these scales will be 
administered at baseline, post-assessment and follow-up.
(g) Food intake in a bogus taste test
During the bogus taste test[102], participants will be instructed to rate and optionally consume 
highly palatable high-calorie food items presented in 3 bowls. See Appendix C for more detailed 
information. This task will be performed at baseline and post-assessment.
(h) Increased preference for delayed rewards 
The Delay Discounting Task with Money and Food[103] examines whether small amounts of food 
would be discounted more steeply than money, as occurs with larger amounts. See Appendix C for 
more detailed information. This will be administered at baseline, post-assessment and follow-up.
(i) Inhibitory control 
The cued Go/No-Go computer task is a classic test of executive function, requiring effortful response 
inhibition, and measures impulse control by the ability to inhibit instigated, prepotent responses. A 
food specific go/no-go task[104] measures impulsivity and response inhibition with respect to food 
and nonfood items. The Stop Signal Task (SST)[105]measures inhibitory control. Participants are 
required to engage in a computer task but withhold their response in the presence of a stop signal. 
An adaptation of the food version of the SST[106] will facilitate a comparison of responses between 
food and non-food categories. See Appendix C for more detailed information. Both of these tasks 
will be performed at baseline, post-assessment and follow-up.
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Mood and emotion regulation
The Emotion Regulation Questionnaire (ERQ)[107] is designed to measure respondents’ tendency to 
regulate their emotions regarding cognitive reappraisal and expressive suppression. The Positive and 
Negative Affect Schedule (PANAS)[108] measures the degree of positive or negative affect 
experienced “right now” in the current study. The Depression, Anxiety and Stress Scale (DASS-
21)[109] evaluates mood, anxiety and stress levels over the previous week. See Appendix C for more 
detailed information. All of these measures will be administered at baseline, post-assessment and 
follow-up.
Within session measures 
Within each training session, i.e. immediately before and after the ABM + real/sham tDCS procedure 
the researcher will administer paper-based Visual Analogue Scales (VAS) assessing current hunger, 
feeling of fullness, urge to eat, urge to binge eat, feeling low, level of tension, level of stress, level of 
anxiety, and any discomfort due to tDCS and ABM in the training session. See Appendix C for more 
detailed information.
Intervention 
In both intervention groups participants will receive six sessions of concurrent ABM and real or sham 
tDCS which will be delivered twice a week for three weeks. A researcher trained in tDCS 
administration will deliver the training sessions. 
Rationale for number of sessions:
Treatment parameters for interventions of ABM and tDCS separately in psychiatric disorder research 
have not yet been standardised and vary from 1-12 sessions across a timeframe of days to multiple 
weeks. Mixed results regarding optimal frequency of ABM sessions and related forms of cognitive 
bias modification has been reported[110]. A maximum accumulative effect of modification efficacy 
at 6 sessions has been found for approach bias modification for alcohol dependence[44]. While 
there is a similar paucity of specifications for treatment parameters within tDCS, multisession NIBS 
interventions are significantly more effective at reducing cravings and strengthening the ability to 
refrain from food consumption than single session protocols in eating disorders and obesity[111]. As 
a single session of tDCS on patients with BED was found to reduce craving and caloric intake[59], it 
was hypothesised that repeated administration of tDCS would enhance this effect and may decrease 
binge eating frequency.
Within session safety procedures
The participant’s blood pressure and heartrate will be taken by the researcher immediately before 
and after the session. While the participant is comfortably seated, the tDCS and ABM will be 
administered at the same time, i.e. participants will engage in ABM training whilst receiving tDCS. 
Each session will last 20 minutes. The ABM training will start 5 minutes after the start of the brain 
stimulation. ABM training will take place over 10 minutes and tDCS will then continue for a further 5 
minutes. Participants will be reminded that they have the option to withdraw immediately and 
terminate their participation in the study if they experience discomfort during tDCS administration, 
or if they wish to withdraw for any reason that they may or may not wish to disclose. 
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Approach bias modification training
The ABM programme will use an implicit learning paradigm, based on a modified version of the Food 
Approach/Avoidance Task (AAT)[85,112–114]. In this task, participants are shown pictures of food 
and control (i.e. neutral office) items. They are required to pull (pictures grow bigger) or push 
(pictures grow smaller) a joystick in response to the outer frame of the picture (round vs. 
rectangular), irrespective of the picture content. The training version of the Food-AAT utilises an 
implicit learning paradigm by presenting all food pictures in the “push” (i.e. avoid) format. The study 
procedure for ABM administration is aligned with previous research[50,115].
Transcranial direct current stimulation
TDCS (both real and sham) will be delivered using a NeuroConn® DC-STIMULATOR PLUS device at a 
constant current of 2 mA (with a 10-second fade in/out) using two 25cm² surface sponge electrodes 
soaked in a sterile saline solution (0.9% sodium chloride). The anode will be placed over the right 
dorsolateral prefrontal cortex (dlPFC) and the cathode over the left dlPFC. This montage has been 
used in sham-controlled studies on food craving, bulimia nervosa and BED[59]. The stimulation site 
will be located using the Beam F3 calculation method, which is based on the International 10-20 
system. TDCS can occasionally result in mild discomfort during administration (i.e., tingling or itching 
sensation, a slightly metallic taste, occasional redness at the site of the electrodes). Fatigue, 
headache, nausea and insomnia have been reported as potential adverse reactions[116]. 
Participants who are at-risk for adverse effects[76] will be excluded from the study at the screening 
stage.
Data analysis
Data will be analysed with the Statistical Package of Social Sciences (SPSS). Feasibility outcome data 
will be analysed with appropriate summary statistics. To determine quality, completeness, and 
variability of the clinical outcome data, descriptive statistical analyses and graphical methods will be 
used. Intent-to-treat analyses will be performed. The size of the treatment effect on each outcome 
measure will be the difference in outcome data between those in the two treatment conditions and 
control condition at post-assessment and follow-up. Group differences will be estimated using linear 
mixed effects regression models, controlling for the baseline level of the outcome. The goal here is 
not to determine significant group differences but to establish a suitably precise effect size for the 
primary outcome at the post treatment assessment. This estimate will be used to guide the sample 
size of a future efficacy trial. Correlational analyses may be computed to analyse relationships 
between outcome variables and influences of potential covariates such as demographic variables, 
i.e. gender, age, BMI and clinical variables, i.e. start/stopping of psychotherapy, psychotropic 
medication and presence of comorbidities. Outcome data already obtained for participants who 
discontinue or deviate from the intervention protocol will be kept and analysed.
PATIENT AND PUBLIC INVOLVEMENT
Patients and/or public were not involved in the study design process, however we will obtain 20 
intervention participants’ qualitative views on their treatment experience in this study to inform 
future clinical trials.
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ETHICS AND DISSEMINATION
Data management and data monitoring
Participant data will be anonymised and all anonymised data will be stored electronically on a 
password protected computer at the IoPPN. All trial data will be stored in line with the General Data 
Protection Regulation (GDPR) 2018. Hard copies of participant-related data (i.e. GP letters) will be 
kept in locked cabinets at the IoPPN, King’s College London. The final trial data set will not be 
accessed by anyone other than members of the research team.
Data will be stored on manual files, university and laptop computers. There will be no personal data 
stored on laptop computers. Confidentiality and anonymity of all personal data will be retained 
throughout the entire study. Manual files will be securely locked in a lockable filing cabinet, and all 
electronic files will be password protected. Identifying information will be removed from the data, 
stored separately and replaced with a numeric identification code. All participants will be allocated a 
numeric code, which will be used to identify their data. The master list of names which correspond 
to each participant's numeric identification code will be stored electronically and will be password 
protected. This information will only be accessible to key researchers involved in the study.
The online component of the assessment will use Online Surveys software (formerly BOS). King’s 
College London uses this software for large scale surveys, and it is fully compliant with UK data 
protection laws. Participants will be emailed the link after the in-person component of each 
assessment session, and instructed to complete the second online component of the assessment 
within 36 hours. Participants will also have the option to receive and complete a hard copy version 
of the questionnaires with a stamped addressed envelope to post back to the study researcher at 
the IoPPN. 
It is intended that the results of this feasibility study will be reported and disseminated at national 
and international conferences. Research findings may also be disseminated through internal 
newsletters and publications in collaboration with Beat, the UK’s largest eating disorder charity.
Owing to the size and nature of this small-scale feasibility study, a data monitoring committee was 
not deemed to be required. There are no scheduled interim analyses and this trial may be 
prematurely discontinued by the Chief Investigator on the basis of new safety information.
Ethics and safety aspects
This study has been approved by the North West - Liverpool East Research Ethics Committee. This 
trial will be conducted in compliance with the study protocol, the Declaration of Helsinki, the 
principles of good clinical practice (ICH-E6 guideline), the ICH-E8 guideline and the principles of GCP 
and in accordance with all applicable regulatory requirements including but not limited to the UK 
policy framework for health and social care research. The ICARUS trial is registered with the 
International Standard Randomised Controlled Trial Number registry (number ISRCTN35717198). All 
participants will be asked by the study researcher to provide written informed consent prior to 
enrolment. Participants who are at-risk for adverse side effects[76]will be excluded from the study at 
the screening stage (i.e. such as those with pregnancy or epilepsy). Current safety parameters of 
tDCS administration regarding voltage amplitude and duration of brain stimulation sessions will be 
adhered to. Participants have the option to withdraw immediately and terminate their participation 
in the study if they experience discomfort during tDCS administration, or if they wish to terminate 
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their participation for any other reason that they may or may not wish to disclose. After each 
training session, participants will complete the tolerance, discomfort and side effects questionnaire 
to report any adverse effects of the intervention training session. The researcher will record this 
description of any reported adverse effects, and record the severity and duration of symptoms and 
how the adverse effect was managed at the following training session. If a participant reports a new 
clinical diagnosis or change in medication during their involvement in the study, a decision regarding 
their continued participation in the study will be made by the research team and withdrawal of the 
participant may be deemed necessary. Standard King’s College London insurance and NHS indemnity 
arrangements apply to this study. To promote study adherence, upon completion of the follow-up 
assessment, each participant will be reimbursed for their time, efforts and travel (£60 for 
assessments and up to £60 for travel expenses). Additionally, participants in the wait-list control 
group will be offered the opportunity to receive 6 sessions of ABM + tDCS after the follow-up. 
DISCUSSION
The ICARUS study represents the first feasibility study that aims to exploit a synergistic therapeutic 
effect by combining two brain-directed interventions in a single treatment intervention for BED. The 
rising clinical need of individuals with BED is currently met with few available psychological and 
neuropharmacological treatment options[117]. Therefore, such research advancing the 
identification and validation of novel therapies is greatly warranted.
This paper delineates the protocol for a feasibility trial which will inform future studies (i.e., provide 
effect sizes for a large RCT) and contribute to the extant research advocating brain-directed 
interventions for BED. The protocol aligns with current parameters of tDCS administration used to 
treat BED and BN[58,59] and utilises a multitudes of measures to identify the most appropriate and 
sensitive tools to detect treatment induced changes across pathological and neurocognitive 
domains. 
Pragmatic concerns related to the recruitment process entail ensuring a sufficient and consistent 
rate of participant enrollment to meet the target sample number within the allocated timeframe. 
Additionally, drop-out rates for CBT treatment among a BED cohort are moderately high (17–
30%)[118], thus study adherence will need to be monitored, with a revision of incentives/ 
reimbursement if necessary. Participants who were randomly allocated to the wait list control may 
avail themselves of 6 sessions of ABM + real tDCS after they have completed the study, which may 
promote recruitment and participant retention. Documenting the management of these issues will 
help to inform the development of a future large-scale RCT of this combined treatment adjunct for 
BED.
To conclude, investigating novel treatments for BED is an imperative issue. Combining ABM with 
tDCS is the strategic amalgamation of two techniques that have already demonstrated therapeutic 
efficacy in their own right. This feasibility RCT will be the first to systematically assess the 
acceptability and efficacy of a noninvasive, safe and potentially effective treatment adjunct to other 
therapies, which will enhance the ability of healthcare services to provide optimal care to patients 
with BED.
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Trial progress
Recruitment will commence in February 2018 and data collection is expected to be complete 
(including follow-up assessments) by April 2020. Any substantial protocol amendments will be 
communicated to investigators via email and to other parties as required. Amendments to the study 
protocol will be reported in publications reporting the study outcomes.
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Figure 1 Study procedure. The 3 assessment time points are baseline, post-assessment and follow-up. IG1 is 
intervention group 1; IG2 is intervention group 2, CG is the wait list control group.
Table 1 Study schedule of measurement and testing time points
________________________________
Approximate time since baseline
Screening of 
potential 
participants
-------
Baseline 
assessment 
(all 
participants)
 -------
Training: 6 
sessions of
ABM + real 
tDCS
0-3 weeks
Training: 6 
sessions of 
ABM + 
sham tDCS
0-3 weeks
Post- 
assessment 
(all 
participants
3 weeks
Follow-up 
(all 
participants)
7 weeks
Informed consent X
EDDS, SCID-I X
TDCS safety screening X
Demographic information X
EDE-Q[83] X X X
Inhibitory control tasks; Go/No-Go 
task[104], SST[106]
X X X
Delay Discounting Task with Money and 
Food[103]
X X X
Food related tasks; Food Choice Task[88], 
FCT, Bogus Taste Test[102]
X X
Approach bias assessment tasks; F-AAT[85], 
SRC[87]
X X X
Questionnaires & scales (incl. at home); 
EDRSQ[119], FCQ-T-r[94], PFS[95], YFAS 
2.0[96], ERQ[107], PANAS[108], BIS-11[120], 
CIA[121], DGI[122], DASS-21[109]
X X X
Pre-[tDCS + ABM] measures:
 -Multiple VAS, blood pressure, pulse
    X                        X
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26
Real or sham tDCS to dLPFC         X                        X
Approach Bias Modification training         X                        X
Post-[tDCS + ABM] measures: 
-Multiple VAS, blood pressure, pulse
        X                        X
Tolerance, discomfort and side effects          X                        X
Acceptability questionnaire X
Blinding assessment questionnaire X
BIS-11; Barrett Impulsiveness Scale, CIA; Clinical Impairment Assessment, DASS-21; Depression, Anxiety and Stress Scale, DGI; Delayed 
Gratification Inventory, EDDS; Eating Disorder Diagnostic Screen, EDE-Q; Eating Disorder Examination, EDRSQ; Eating Disorder Recovery 
Self Efficacy Questionnaire, ERQ; Emotion Regulation Questionnaire, FCQ-T-r; Food Cravings Questionnaire Trait Version – reduced, 
PANAS; Positive and Negative Affect Schedule, PFS; The 21-item Power of Food Scale, SCID-I; Structured Clinical Interview for Diagnostic 
and Statistical Manual (DSM) Axis I Disorders, SRC; Stimulus Response Compatibility Task, SST; Stop Signal Task, YFAS 2.0; The Yale Food 
Addiction Scale Version 2.0, .
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Note from the Editors: Instructions for reviewers of study protocols
Since launching in 2011, BMJ Open has published study protocols for planned or ongoing research 
studies. If data collection is complete, we will not consider the manuscript.
Publishing study protocols enables researchers and funding bodies to stay up to date in their fields 
by providing exposure to research activity that may not otherwise be widely publicised. This can help 
prevent unnecessary duplication of work and will hopefully enable collaboration. Publishing 
protocols in full also makes available more information than is currently required by trial registries 
and increases transparency, making it easier for others (editors, reviewers and readers) to see and 
understand any deviations from the protocol that occur during the conduct of the study.
The scientific integrity and the credibility of the study data depend substantially on the study design 
and methodology, which is why the study protocol requires a thorough peer-review. 
BMJ Open will consider for publication protocols for any study design, including observational 
studies and systematic reviews.
Some things to keep in mind when reviewing the study protocol: 
 Protocol papers should report planned or ongoing studies. The dates of the study should be 
included in the manuscript. 
 Unfortunately we are unable to customize the reviewer report form for study protocols. As 
such, some of the items (i.e., those pertaining to results) on the form should be scores as 
Not Applicable (N/A).
 While some baseline data can be presented, there should be no results or conclusions 
present in the study protocol. 
 For studies that are ongoing, it is generally the case that very few changes can be made to 
the methodology. As such, requests for revisions are generally clarifications for the rationale 
or details relating to the methods. If there is a major flaw in the study that would prevent a 
sound interpretation of the data, we would expect the study protocol to be rejected. 
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